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ABSTRACT

Diabetes mellitus, the third most common disease in the world, is a chronic
metabolic disorder caused by a failure of insulin production and/or an inability to respond
to insulin. Specifically, type 1 diabetes is a disorder characterized by targeted
autoimmune-directed destruction of a patient’s β-cell population within the pancreatic
islets of Langerhans. The current primary treatment for type 1 diabetes is daily multiple
insulin injections. However, this treatment cannot provide sustained physiological
release, and the insulin amount is not finely tuned to glycemia. Pancreatic transplants or
islet transplants would be the preferred treatment method but the lack of donor tissue and
immunoincompatibility has been shown to be a roadblock to their widespread use.
The objective of this project is to develop an effective strategy for the treatment of
type 1 diabetes using β-cells based replacement therapy. To improve the viability of
transplanted β-cells, one novel approach is to transplant optimal size range of β-cell
spheroids rather than cell suspension. Uniform sized multicellular spheroids can be
coated with a thin layer of non-degradable hydrogel for immunoisolation. In addition, the
survival of spheroids of optimized size can be further improved with a novel coating of
multiple layers of human mesenchymal stem cells (hMSCs), a cell type that has profound
immunoregulatory effect, to prevent graft rejection. To prevent hMSC migrate away from
spheroids, another layer of non-degradable hydrogel can be added. To further improve
the viability and suppress the immune rejection, spheroids will be encapsulated with
nanoparticles loaded with angiogenic and immune regulatory molecules. By this means
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the spheroid will passively evade the complications of stressors in addition to actively
modulating the immune microenvironment for regulatory tolerance and long-term
engraftment.
Firstly, through optimizing our hydrogel systems based on poly (ethylene glycol)
(PEG), we have created specific niche for β-cells to form artificial islets in vitro. We have
found that the optimal condition is the concentration of PEG at 5% and the ratios of 4arm thiolated PEG to 4-arm PEG acrylate at 1:2. Conjugated with adhesive peptides,
especially, RGD at 0.2 mM, can significantly promote the glucose stimulated insulin
secretion of encapsulated β-cells. Secondly, we have fabricated different sizes of
uniformed β-cells spheroids through our designed high-throughput automatic spheroids
maker. Beta-cells in the spheroids of 200 µm exhibited largest insulin secretion based on
glucose stimulus when compared to others with sizes of 100, 300, 400 and 500 µm. The
novel core-shell structured spheroids-hMSCs complex was successfully achieved.
Methylcellulose hydrogel was applied as physical barrier on the surface of β-cells
spheroids to inhibit invasion of hMSCs. Human MSCs prevented apoptosis of β-cells
spheroids and benefited insulin secretion when exposed to pro-inflammatory cytokines.
Thirdly, immune regulatory molecules [leukemia inhibitory factor (LIF) and interleukin
10 (IL-10)] and angiogenic molecule [vascular endothelial growth factor (VEGF)] loaded
poly (lactic-co-glycolic acid) (PLGA) nanoparticles have been successfully fabricated
through solvent extraction/evaporation technique. These growth factors can be controlled
release about 6 weeks. The bioactivity of released VEGF has been confirmed by the in
vitro HAEC proliferation assay. Finally, β-cells spheroids were transplanted under the
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kidney capsule to treat diabetic mice. Beta-cells spheroids kept the glucose level of
diabetic mice constant. Co-transplanted hMSCs suppressed the host inflammation
response, activated the regulatory T cells and also promoted angiogenesis at the
transplantation site. The β-cells spheroids/hMSCs/hydrogel complex initiated a mild
inflammatory response. The LIF and IL-10, and VEGF loaded complex can further
inhibited this response and promoted blood vessel network formation at the
transplantation site. Our approach holds a great potential to treat type 1 diabetes
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CHAPTER ONE
1. INTRODUCTION
1.1 Type 1 diabetes and current treatments
Diabetes mellitus is one of the most common metabolic diseases, which has
become the third most common disease in the world. Around 285 million people
worldwide suffer from various types of diabetes in 2012, and the number of people with
diabetes will reach to 439 million by 2030. And the complications followed by diabetes
mellitus include coronary heart disease, kidney failure, blindness, limb amputations, and
premature death.
Type 1 diabetes, referred to insulin-dependent diabetes mellitus, is an
autoimmune disease resulting form the destruction of β-cells located in the islets of
Langerhams of pancreas by autoantigen-reactive T lymphocytes which produce immune
factors to attack and destroy β-cells in the pancreas. Once β-cells are destroyed, the
ability to secrete insulin in response to control the blood glucose level is inhibited, and
then leading to hyperglycaemia at clinical diagnosis. In the United States there are 30,000
new cases annually with 1 in 300 children affected.
To date, no effective treatment is available for type 1 diabetes in clinical settings.
The exogenous insulin injection therapy is the current main treatment. However, the
multiple injections are inconvenient and painful and may lead to infection at the site of
injection. Pancreas transplantation is a clinical option available to cure type 1 diabetes.
But complications are followed immediately after surgery including thrombosis,
pancreatitis, infection, bleeding, and rejection. Rejection is a serious condition and ought

to be treated immediately. Patients must take a long-term immunosuppressive therapy.
Transplantation of islets, the parts of the pancreas that can make insulin, can avoid a
delicate surgical procedure and reduce the risk followed by the transplantation. However,
for decades, the clinical application of islet transplantation is also limited by the
shortcoming of immunosupression therapy and the shortage of donor tissues. In
pancreatic islet transplantation, while efforts have been centered on systematic
modulation of host immune responses for transplantation tolerance, strategies that render
the allograft itself resistant to host immune insult have not been adequately explored. Islet
encapsulation has been attempted as an immunoisolation device to facilitate the
transplantation of islets without the need for immunosuppression for decades.
Immunoisolation of islets aims to overcome the immune-mediated destruction of the
donor tissues without requiring toxic immunosuppression agents. The strategy of
immunoisolation means encapsulating islets within a semi-permeable structure made of
biomaterials with good biocompatibility. Immunoisolation of islets also offers a
possibility of using islets gained form animals, or insulin-producing cells induced from
stem cells or pancreatic precursor cells, thus enlarging the potential sources of donor
tissues. However, an optimal encapsulation device that allows sufficient oxygen and
nutrient exchange while protecting from immune rejection response and promoting
vascularization is still lacking.
1.2 Study objectives and specific aims
In this study, we will develop a comprehensive strategy for the treatment of type 1
diabetes using β-cell based replacement therapy. To improve the viability of transplanted
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β-cells, one novel approach is to transplant optimal size range of β-cell spheroids. We
will focus on a novel and unique automatic robotic fabrication/microencapsulation
system that can produce uniform-sized multicellular spheroid ranging anywhere between
100 µm to 1000 µm. It can also allow coating of the islets or islet-like spheroids with
multiple layers for immunoisolation and immunomodulation. We will coat the islets or
spheroids with a non-degradable methylcellulose first, then with multiple layers of human
mesenchymal stem cells (hMSCs), which demonstrated anti-immune and antiinflammatory effects. Lastly, we will have a porous non-degradable polymer layer for
further protection and promoting vascular formation surrounding the encapsulated islets.
Porous layer will be loaded with nanoparticles impregnated with angiogenic factors and
immune regulatory molecules to enhance blood vessel formation around the encapsulated
spheroids and in the same time further suppress the host immune response (Schematic 1).
By this means the islets will passively evade the complications of stressors in addition to
actively modulating the immune microenvironment for regulatory tolerance and longterm engraftment. Islet microencapsulation can not only serve as a physical barrier
deterring host immune recognition, but also function as a cargo carrier slowly releasing
immune-modulatory molecules that accommodate the allograft into a local permissive
cytokine milieu for long-term engraftment.

1.3 Dissertation organization
The following manuscript is arranged in chapters that highlight individual studies
that relate to the overall aims of the project. Chapter 2 focuses on highlighting existing
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strategies currently being investigated for type 1 diabetes treatment. In Chapter 3, we
have created specific niche for β-cells through developing a series of hydrogels based on
polyethelene glycol (PEG) and addehisve peptides RGD, YIGSR and IKVAV. In Chapter
4, we developed a fully robotic biofabrication method to produce uniform size
multicellular β-cells spheroids in large scale. Furthermore, we have constructed the
complex of islet-like spheroids with multiple layers of hydrogels and hMSCs for
immunoisolation and immunomodulation. To further improve the viability and suppress
the immune rejection, in Chapter 5, we have loaded angiogenic and immune regulatory
molecules like VEGF, IL-10 and LIF, into degradable poly (lactic-co-glycolic acid)
(PLGA) nanoparticles and loaded nanoparticles into last layer hydrogels coating, for
sustained release; we then inspected the biological activities of released IL-10 and LIF on
survival and function of β-cells spheroids against pro-inflammatory cytokines, and the
bioactivity of VEGF released from nanparticles. In Chapter 6, we have evaluated of βcells/MSC hybrid spheriods for the treatment of type 1 diabetes in vivo. Chapter 8
summarizes overall conclusions drawn from the body of work and discusses
developments related to the presented research.
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CHAPTER TWO
2. BIOENGINEERING STRATEGIES FOR TYPE 1 DIABETES TREATMENT
2.1 Introduction
Diabetes mellitus is a chronic endocrine disease that is attributed to insulin
deficiency. Type 1 diabetes mellitus , occurring in children or young people, is an
autoimmune disorder in which β-cells located in pancreatic islets are damaged and no
longer able to secrete insulin. Every year around 15,000 patients are diagnosed with type
1 diabetes in the United States, adding to the three million existing type I diabetes
patients.
The current clinical treatments for type 1 diabetes include exogenous insulin
administration therapy and pancreas transplantation. Even though routine glucose
monitoring and exogenous insulin therapy has been the common treatment, the lack of
precise control of blood glucose with this therapy results in many complications, such as
retinopathy (loss of vision), nephropathy (renal failure), and neuropathy (foot ulcers with
the risk of amputation, even cardiovascular symptoms) [1]. Pancreas transplantation is an
option of clinically available β-cells replacement to cure the disease. However, the
procedure involves major surgery and long-term immunosuppression therapy which will
leads to severe side effects [2]. Pancreas transplantation is not an optimal therapeutic
option for the vast majority of diabetic patients [3].
Many new strategies for type 1 diabetes are under clinical trials. In order to
reduce the risks of developing diabetes-related complications, novel methods in the
insulin formulations and delivery systems have been investigated to improve the blood
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glucose level control. Islet transplantation has also been studied as a potential option for
the treatment of type 1 diabetes. Compared to pancreas transplantation, islet
transplantation is more effective and less invasive. But islet transplantation cannot avoid
similar problems to pancreas transplantation such as the limitation of donor tissue and
long-term immunosuppression therapy if naked islets are used. An immunoisolated
bioartificial pancreas (BAP) has been developed based on bioengineering strategies for
avoiding immunosuppression. BAP allows the passage of oxygen, glucose, nutrients,
waste products, and insulin, but blocks the penetration of immunocompetent cells and
immune response associated biologics, such as antibodies and complements [4].
Imunoisolation technology offers a possibility for cell-based therapy to transplant β-cells
or islets from animal sources, or new insulin-producing β-cells induced from other
sources like stem cells and pancreatic precursor cells, thus expanding the sources of
donor tissues. The generation of insulin-producing β-cells through in vivo regeneration or
in vitro differentiation from stem cells has been investigated [5, 6].
There are several excellent review articles that offer a very detailed and
comprehensive overview regarding the use of islet encapsulation and cell-based therapy
for type 1 diabetes treatment [7-10]. Here, we will present a more detailed overview on
bioengineering strategies for type 1 diabetes treatment. We will have a comprehensive
review on bioengineering strategies with a focus on insulin delivery systems, BAP
fabrication, transplantation of β-cells and inducing β-cells from other cell sources, and so
on. Finally, we will also discuss major challenges using existing strategies and future
directions for type 1 diabetes treatment.
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2.2 Diabetes types and current treatments
Diabetes mellitus is one of the most common metabolic diseases and has become
the third most common disease following cardiovascular diseases and cancers. Around
347 million people worldwide suffered from various types of diabetes in 2012, and the
projected number of diabetes patients will reach to 439 million by 2030 [11]. The
complications followed by diabetes mellitus include coronary heart disease, kidney
failure, blindness, limb amputations, and premature death [12]. About 25.8 million
Americans have diabetes and a total cost of diagnosed diabetes is $245 billion in 2012.

2.2.1

Diabetes types
Diabetes mellitus is a group of chronic metabolic diseases characterized by a

deficit in β-cells mass and a disregulation of glucose metabolism, resulting in many
complications. The classical symptoms include polyuria, polydipsia and polyphagia.
There are three types of diabetes mellitus: type 1 diabetes, type 2 diabetes, and
gestational diabetes. Type 1 diabetes is an insulin-dependent diabetes mellitus, which is
believed to be an autoimmune disease leading to the destruction of β-cells in the islets of
Langerhams. Once β-cells are destroyed by autoantigen-reactive T lymphocytes, the
ability to secrete insulin in response to blood glucose increase is compromised, leading to
hyperglycaemia. Type 2 diabetes is a non-insulin-dependent diabetes mellitus or an adultonset diabetes. It is characterized as insulin resistance, meaning cells fail to use insulin
properly, leading to hyperglycaemia. The development of type 2 diabetes is caused by a
combination of lifestyle and genetic factors. Obesity is the primary cause of type 2
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diabetes in people who are genetically predisposed to the disease. Exercise and dietary
modification are the first steps of disease management. If blood glucose levels are still
high by these measures, medications such as Metformin or insulin may be needed.
Gestational diabetes is a condition in which pregnant women, who have never had
diabetes before, reveal high blood glucose level during pregnancy. Pregnancy hormones
lead to insulin resistance and then hyperglycaemia. Gestational diabetes generally has
few symptoms. It is commonly diagnosed by a screening test during pregnancy. Around
3-10% pregnant women will have gestational diabetes depending on the population [13].
Women with gestational diabetes are at increased risk of developing type 2 diabetes after
pregnancy. Most patients are treated only with diet modification and moderate exercise,
but some will have to take anti-diabetic drugs, such as insulin, if the blood glucose level
is too high [14].

2.2.2

Current clinical treatments for type 1 diabetes
Exogenous insulin injection therapy is the current main treatment for type 1

diabetes. It includes multiple/daily injections and insulin pump therapy (chronic
subcutaneous injection). The multiples injections are inconvenient and painful and may
lead to infection at the site of injection, giving rise for the increased research for new
methods of treatment. For insulin pump therapy, the long-term injection at the same place
can result in lipodystrophy. Although insulin-based therapy allows a monitor of the
control of blood glucose levels through daily glucose monitoring, strict control of blood
glucose levels can be difficult to achieve due to environmental variations, such as
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exercise, diet, pregnancy, or age. The exogenous insulin injection therapy may lead to
long-term complications, such as retinopathy, nephropathy, and neuropathy [15].
Currently, pancreas transplantation is a clinical option available to treat type 1
diabetes. In this procedure, the recipient’s native pancreas is left in place to prevent the
rejection of the donor pancreas which would leads to life-threatening diabetes quickly,
thus the donor pancreas is placed in a different location [16]. In patients with type 1
diabetes who have suffered the destruction of their kidney, the pancreas transplantation
usually is performed along with kidney transplantation [17]. More than 90% of pancreas
transplantations

are

simultaneous

pancreas-kidney

transplants.

Complications

immediately following surgery include thrombosis, pancreatitis, infection, bleeding, and
rejection. Rejection is a serious condition and ought to be treated immediately. Patients
must undergo a long-term immunosuppressive therapy [18].

2.2.3

New treatments under clinical trial and development
The development of insulin administration by alternative routes has made

remarkable progress over the last decade. The ultimate goal is to better simulate the
physiological fluctuations of endogenous insulin release and thus leading to a better
blood glucose metabolism and control. The current main alternatives for insulin delivery
include nasal, pulmonary, dermal, rectal, and oral routes [19].
Islet cell transplantation is an experimental procedure that only transplants the
islet parts that can make insulin. Islet transplantation has the potential to be widely used
for type 1 diabetes, since this procedure can avoid a delicate surgical procedure and
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reduce the risk followed by the whole pancreas transplantation [2, 20]. Islet
transplantation includes two steps: the isolation of islets from donor pancreas tissue and
the transplantation. The transplantation procedure is shown in Figure 2.1 [21]. Islets are
injected into the hepatic portal vein, from where islets will flow into liver sinuses, which
are well perfused. In this case, islets are not transplanted in the recipient’s pancreas
because the pancreas is highly sensitive to any injury, which may lead to severe
pancreatitis with accompanying pain and tissue destruction.

Figure 2. 1 Islet transplantation for the treatment of type 1 diabetes in clinical [21].

For decades, the clinical application of islets transplantation was also limited by
the shortcoming of immunosupression therapy and the shortage of donor tissues. Using
biomaterial, scientists paid attention to immunoisolating islets from host immune systems
based on various bioengineering approaches [22]. Using immunoisolated islets for
transplantation can minimize, and even eliminate immunosuppressive needs theoretically
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[23, 24]. Immunoisolation of islets offers a possibility of using islets derived from
animals, or insulin-producing cells obtained from stem cells or pancreatic precursor cells,
thus enlarging the potential sources of donor tissues. To this end, the generation of new
insulin-producing cells by in vivo regeneration or by in vitro differentiation of stem cells
has become a major effort in diabetes research [25, 26].
Since type 1 diabetes is one of the most common autoimmune diseases,
considerable experimental and clinical progress has been made in understanding of its
immunopathogenesis [27]. This knowledge has been used to develop immunopreventive
and immunomodulatory treatments for type 1 diabetes [28, 29].

2.3 Bioengineering strategies for type 1 diabetes treatment
Several novel bioengineering approaches are applied in insulin administration,
islets transplantation, and cell-based therapy for type 1 diabetes treatment, such as
microspheres and nanoparticles for insulin controlled release systems, hollow fibers and
chamber diffusion device for islets immunoisolation, and hydrogels for β-cells
transplantation.

2.3.1

Insulin control release
Insulin was firstly discovered by Banting and Best in 1922 [30]. The role of

insulin is to change extra glucose into two storage forms, glycogen and triacylglycerols,
and maintain blood glucose levels. The main method for insulin administration is
subcutaneous injection because of insulin’s large molecular size, hydrophilicity and low
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permeability. However, injection therapy is burdensome and has a low efficiency for
insulin targeting to the liver, which is the primary organ of action. Only about 20% of the
insulin reaches the liver after injection [31]. Various technologies have been investigated
for replacing the insulin injections. Therefore, drug delivery systems have been paid
attention to for the development of non-injectable routes. The main alternatives routes
studied for insulin deliveries include nasal, pulmonary, dermal, rectal and oral routes. In
this section we will discuss the different drug delivery strategies available (molecular,
formulation, and device) and their current and potential applications with respect to the
different insulin delivery routes.

2.3.1.1 Molecular engineering
Insulin is a polypeptide (molecular weight: 5800 Da) secreted by β-cells which
consists of a 21-amino acid A chain and a 30-amino acid B chain, linked by two disulfide
bonds, and a third disulfide bond occurs within the A chain [32]. Molecular engineering
strategies are to modify insulin to improve its pharmacodynamic properties (insulin
analogs) and prevent it from proteolytic degradation (insulin conjugates). An insulin
analog is another form of insulin which results from changing the amino acid sequence of
insulin. The characteristics of insulin such as absorption, distribution, metabolism and
excretion are optimized for improving pharmacodynamic properties of the applied insulin
by adjusting the amino acid sequence of insulin. Insulin conjugates is the chemically
modified formation of insulin for protecting the insulin from proteolytic degradation or
improving its properties such as solubility, permeability, stability and circulation half-
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life.
2.3.1.1.1

Insulin analogs

Through the molecular engineering approaches, the amino acid sequences of
insulin are altered to fabricate two types of insulin analogs. One is rapid-acting insulin
analogs which are designed to provide a bolus level of insulin; another is long-acting
analogs which are required to supply a basal level of insulin. Three rapid-acting analogs
and two long-acting analogs are shown in Table 2.1. Aspart, Lispro and Glulisine insulin
are rapid-acting analogs [33]; Glargine and Detemir analogs are long-acting analogs [34].
Compared to human insulin, the different amino acids of insulin analogs are labeled.
Long-acting analogs with the slowing absorption property can last 20-24 hrs in the body
after injection and decrease nocturnal hypoglycemia. Rapid-acting analogs increase the
rate of absorption after injection and last longer than regular insulin.
Table 2. 1 Insulin analogs by amino acid substitutions [33].
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2.3.1.1.2

Insulin conjugates

Insulin conjugates have been investigated with several macromolecules such as
poly (ethylene glycol) (PEG) [35, 36], polysialic acids [37, 38], albumin [39, 40], and
chitosan [41]. For example, one of the most important modifications of insulin is the
hexyl-insulin mono-conjugate 2 (HIM2), which has been introduced by the NOBEX
corporation [35]. The HIM2 molecule was made by covalently linking a single, low
molecular weight ampiphlic oligomer to the free amino acid group on the Lys-B29
residue of recombinant human insulin through an amide bond. The oligomer was
synthesized by binding a lipophilic alkyl unit to a hydrophilic PEG unit. This conjugation
conferred many advantageous properties to the insulin molecule, such as more lipid and
water solubility. These properties can be used to manufacture more varieties of
formulation than ordinary insulin [42, 43]. Moreover, an insulin prodrug was designed by
conjugating insulin to a PEG (40 kDa) containing sulfhydryl moiety. After subcutaneous
injection, the insulin prodrug could extend glucose-lowering effects compared to the
native hormone [44]. Bile acids [45, 46] or fatty acids [47] were also bonded with insulin
to improve the stability of insulin.

2.3.1.2 Formulation engineering
The insulin administration routes and the required pharmacokinetic property
decide the formulation of insulin. Formulation engineering aims to reach the required
delivery profile. Hydrogels, patches, dry powders, microspheres, and nanoparticles have
been applied to control the release of insulin for novel delivery routes such as nasal, oral,
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pulmonary, and rectal.
2.3.1.2.1

Hydrogels

Hydrogels are three-dimensional (3D) networks of hydrophilic polymers that can
entrap drugs and biomolecules under certain conditions and then releases the drugs or
biomolecules in a controlled slow release manner. Thus, a higher concentration of the
drugs and biomolecules can be loaded inside the hydrogels, which can be formulated to
respond to various environmental signals such as pH [48], temperature [49], light [50],
glucose [51], antigens [52], ultrasound, and so on, to release the drugs or biomolecules.
These stimuli-responsive polymeric hydrogels have been extensively studied and used as
“smart” carriers for the control release of insulin.

2.3.1.2.1.1 pH-sensitive hydrogels
All the pH-sensitive hydrogels include acids, such as sulfuric and carboxylic
acids, or bases, such as ammonium salts group, for gaining or releasing protons in
response to changes in environmental pH. Acidic hydrogels accept protons, swell at high
pH, and shrink at low pH. In contrast, basic hydrogels exhibit opposite swelling
behaviors in response to pH. The pH-sensitive hydrogels have shown the potential for the
application as oral delivery of insulin [53-55]. Through controlling the swelling/shrinking
properties, encapsulated insulin can be protected from degradation in the acidic
environment in stomach (pH 1-2) [56, 57] and then be released in the basic environment
of intestine (pH 6-7) [58, 59]. For example, hydrogels containing poly(mehacrylic acid)
grafted with PEG were investigated for their potential as oral insulin carriers [54]. The
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results showed insulin loaded hydrogels induced a hypoglycemic effect and an increase in
insulin levels, proving that insulin was still biologically active. Tuesca et al. [60]
demonstrated the feasibility of combing insulin PEGylation with pH-sensitive hydrogels
for oral insulin delivery.

2.3.1.2.1.2 Thermosensitive hydrogels
Polymers comprising both hydrophobic and hydrophilic parts in their molecular
structure exhibit thermo-sensitive properties. The thermo-sensitive hydrogel is usually
designed for application as an injectable local drug delivery system. The insulin-loaded
hydrogel is a flowing solution at ambient temperature and turns into a non-flowing gel at
body temperature after being injected into body, and starts to release insulin at local sites
[61, 62]. A study was aimed at developing a delivery system for the controlled slow
release of insulin, based on chitosan-zinc-insulin complex incorporated into a poly(lactic
acid)-poly(ethylene glycol)-poly(lactic acid) (4500 Da) thermo-sensitive polymer [63].
The addition of zinc to insulin reduced the initial burst, stabilized the insulin as compared
with its monomeric state by forming reversible complex through a zinc-coordinated
insulin hexamer, and controlled the overall release rate.

2.3.1.2.1.3 pH/thermo-sensitive hydrogels
The pure thermo-sensitive hydrogel is not suitable for the deep injection into the
tissue because of the gelation formation inside the needle during the injection procedure.
The pH/thermo-sensitive hydrogels can solve this problem. The polymer requires the
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stimulation of both pH and temperature for the gelation process [64]. As Figure 2.2
shown, a pH- and thermo-sensitive hydrogel was prepared by adding pH-sensitive
sulfamethazine oligomers to either end of a thermosensitive poly(ε-caprolactone-colactide)-poly(ethylene glycol)-poly(ε-caprolactone-co-lactide) block copolymer, which
exhibited a pH-sensitivity around pH 7.4 as well as a temperature-sensitivity around 37
º

C [65]. Another study used poly(β-amino ester) as a duo-functional group for controlled

drug/protein delivery when responding to pH and thermal stimulations [66].
2.3.1.2.1.4 Glucose-sensitive hydrogels
Glucose-sensitive hydrogels attracted lots of attention due to their glucose sensing
ability, which may allow for automatic initiation or shut-off the insulin delivery. One
series of glucose-sensitive hydrogels was prepared by mixing glucose-containing
polymers with PEGylated concanavalin A (conA). Tang et al. [67] reported a polymer
produced by crosslinking two dextrans of different molecular weights. The smaller
dextran was covalently grafted with conA. This material was then mixed with the larger
unfunctionalized dextran, allowing easy control of the overall amount of grafted conA in
the material. Insulin was initially bound to the conA, which was used to control the
delivery of glycosylated insulin. The affinity of conA for dextran provided additional
affinity crosslinks, which were competitively inhibited by free glucose, resulting in a
decrease in total crosslink density and increase in permeability to proteins. Moreover,
Kim’s et al [68] demonstrated that glucose could be incorporated into the polymer
backbone by copolymerization of allyl glucose with comonomers, such as 3sulfopropylacrylate, potassium salt, N-vinyl pyrrolidone, and acrylamide. ConA was
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grafted with five PEG molecules to improve its stability. Although all of the glucosesensitive hydrogels are used to develop modulated insulin delivery systems, many
improvements need to be achieved before they become clinically useful. The response of
these hydrogels to changes in the environmental glucose concentration needs to be
improved; also the speed for hydrogels returning to their original states needs to be
increased after responding to the changing glucose concentration.

2.3.1.2.2

Microspheres

Polymer micropsheres are small (less than 2 µm in size), thermoplastic spheres,
which can be used in controlled release of insulin because of their ability to increase the
stability of insulin and the protection of encapsulated insulin from enzymatic degradation.
Microspheres improve the insulin absorption due to the distribution of microspheres in
the body. Microspheres are expected to accumulate in the liver where insulin can
efficiently suppress elevated glucose production.
Since 1986, Damge et al. [69] fabricated insulin loaded isobutyl 2-cyanoacrylate
microspheres to treat streptozotocin-induced diabetic rats. Significant reductions in blood
glucose levels were observed following administration of these microspheres [70, 71].
Since administration of insulin requires repeated dosing, the use of non-biodegradable
microspheres posed a question with regard to the toxic effects of their accumulation in
the body. Hence biodegradable microspheres such as ones made from a blend of
poly(lactic acid) [72], poly(ε-caprolactone) [73], chitosan [74], and poly (lactide-coglycolide) (PLGA) [75], were investigated. The water/oil/water (w/o/w) double emulsion

18

technique has been widely used for encapsulation of hydrophilic macromolecules in
microparticles [76]. The microsphere drug delivery system has been investigated to
increase the poor permeability across intestinal epithelia and avoid destruction by
proteolytic intestinal enzymes.

Figure 2. 2 Insulin loading and release from pH/thermo-sensitive hydrogels. (A)The
polymer solution in sol state at 10 °C and pH 7.0 with the ionic complex between insulin
and PAE–PCL–PEG–PCL–PAE. (B) The gel formed by insulin free PAE–PCL–PEG–
PCL–PAE after injection to human body (37 °C and pH 7.4). (C) Insulin release from gel
by polymer degradation [65].
As discussed earlier, stimuli-responsive “smart” hydrogels have attracted a great
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deal of interest [77]. A pH-sensitive copolymeric hydrogel microspheres were prepared
from N-vinylcaprolactam and methacrylic acid monomers by free radical polymerization
offered 52% encapsulation efficiency and evaluated for oral delivery of human insulin
[78]. Kumar et al. [79] prepared pH-sensitive hydrogel microparticles based on poly
(methacrylic acid), and the result was shown that insulin dose released from
microparticles were sufficient to control the blood glucose level of fed diabetic rats
between 100 and 300 mg/dL.

2.3.1.2.3

Nanoparticles

Nanoparticles are defined as colloidal particles ranging in sizes less than 1000
nm. A variety of nanoparticulate systems including nanospheres, nanovesicles,
nanoplexes, nanocapsules, lipsomes, and a wide array of polymers were developed in
nanoparticulate systems. The choice of polymers should be based on the required release
profile, administration route, drug to be loaded, and the degradation property. Common
polymers used for the insulin delivery system include PLGA [80, 81], chitosan, alginate
[82], poly(ε-caprolactone) [83], polyalkycyancrylates [84, 85], and polymethacrylic
acid/acrylates [86]. Using a double-emulsion/solvent technique, insulin was encapsulated
in PLGA nanoparticles [87]. Insulin loaded in PLGA-Pluronic F68 can overcome the
gastrointestinal barrier which can be used as an oral administration of insulin [81]. In vivo
experiments showed that the insulin loaded PLGA nanoparticles could decrease animal
blood glucose. Insulin loaded chitosan nanoparticles were tested in nasal and oral
delivery routes. As a nasal delivery system, insulin loaded PEG-g-chitosan nanoparticles
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in rabbits improved the absorption of insulin compared to control insulin solution and
mix of insulin and PEG-g-chitosan [88]. The insulin loaded chitosan nanoparticles have
been tested in oral administration [89-91].

2.3.1.3 Device engineering
Some insulin release device designs, such as insulin pumps, insulin pen injectors,
inhalation, and transdermal patches are used as a straightforward approach to increase
patient acceptance and compliance [92, 93]. Delivery systems are being engineered for
reproducible dose delivery. Inhalation devices are designed to delivery insulin powder
through the pulmonary system. A blister pack of insulin powder is loaded into the inhaler
and then the powder is dispersed into a standing cloud within the transparent chamber for
the patients [94, 95]. Insulin pen, insulin jet injectors, and insulin pumps are non-needle
injectors for people who prefer not to use a regular needle and syringe. Insulin pumps can
deliver insulin constantly and can help to control glucose level all the time, even when
patients are sleeping, which may avoid glucose swings and overall provide tighter control
of glucose levels. In addition, pumps will allow patients to have a more flexible meal and
activity schedule [96]. Glucometers are designed to monitor the blood glucose levels and
are currently widely used by patients [97].

2.3.2

Islets transplantation
The transplantation of islets of Langerhans is a potential option for curing type 1

diabetes. The procedure can avoid the complications followed by major surgery
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compared to whole pancreas transplantation. However, islets transplantation still faces
the problems of the long-term administration of immunosuppressive agents with severe
side effects, and the shortage of donor tissues. To solve these issues, the immunoisolation
of islets with a semi-permeable membrane, or bioartificial pancreas (BAP), has been
attempted. Using novel bioengineering approaches, a bioartificial pancreas has been
fabricated for immunoisolating islets away from the host immune systems. Many groups
have reported that BAP functions very well in small animal models. In this review, we
overview the current techniques for the islets immunoisolation such as macro/micro
encapsulation and conformal coating, and discuss some novel techniques for the
modification of islets, such as chemical and cell modification.

2.3.2.1 Islets immunoisolation
Immunoisolation of islets is a technology becoming accepted to overcome the
immune-mediated

destruction

of

the

donor

tissues

without

requiring

toxic

immunosuppression agents. The strategy of immunoisolation means encapsulating islets
within a semi-permeable membrane made of biomaterials with good biocompatibility.
Immunoisolation devices include three different types of encapsulated systems based on
different encapsulation techniques: macro-scale encapsulation, micro-scale encapsulation,
and nano-scale encapsulation [22].
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2.3.2.1.1

Macro-scale encapsulation

Macro-scale

encapsulation

includes

two

categories:

intravascular

and

extravascular. The intravascular devices usually contain hollow fibers, which are
perfused with blood. Extravascular devices such as hollow fibers, diffusion chambers,
and hydrogels sheets, are implanted outside of the vasculature.

2.3.2.1.1.1 Intravascular devices
In the intravascular devices, the islets are encapsulated in hollow fibers sealed
with semi-permeable membranes. The device is similar to a dialysis device in which
blood is perfused in the hollow fiber and islets are placed around the fibers. The device is
directly connected to the host systemic circulation, resulting in improving the diffusive
exchange rate [98-100]. Ikada et al. [100] designed a BAP based on poly(ethylene-vinyl
alcohol) (PVA), which was properly controlled in response to glucose in
pancreatectomized pigs. However, these devices are hard to implant into a body and
require some anticoagulation treatment.

2.3.2.1.1.2 Extravascular devices
Extra vascular devices entrap islets in a space surrounded by a semi-permeable
membrane. Compared to intravascular devices, these devices are easily implantable and
have the advantage of biocompatibility. Islets are contained in a diffusion chamber
surrounded by semi-permeable membranes [101, 102]. The structure of the diffusion
chamber is rather simple and the optimal membrane with desired pore size can be chosen.
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However, islets tend to clump up with each other and undergo central necrosis. Seeding
islets within hydrogels can avoid this clumping and improve islets function [4]. Macroencapsulation encapsulates islets in hydrogels such as agarose, alginate [103, 104],
polyurethane, PVA, and chitosan-polyvinylpyrrolidone hydrogel. For example, a unique
continuous amphiphilic network membrane created for macroencapsulation and
immunoisolation of porcine islet cells has been studied based on hydrophilic poly (N, Ndimethyl acrylamide) and hydrophobic/oxyphilic polydimethylsiloxane chains [105].

2.3.2.1.2

Micro-scale encapsulation

In micro-scale encapsulation, generally one or a few islets are encapsulated within
a microcapsules surrounded by semi-permeable membrane. Microcapsules are smaller
than macrocapsules and are spherical in shape, which offers a large volume-to-surface
area ratio. They can be implanted into patients through simple procedures without major
surgery. Generally, microcapsules are fabricated from polymers that form hydrogels
under certain conditions. They are derived either naturally or through synthetic routes.
The polymers include the natural biomaterials such as alginate, agarose, and the synthetic
biomaterials including polyacrylates [106, 107] and PEG [108, 109].

2.3.2.1.2.1 Alginate
Alginate microcapsules are made by Ca2+ or Ba2+ cross-linked gel formation. The
traditional type of alginate microcapsules is alginate-poly-L-lysine alginate (APA)
microcapsules. APA microencapsulation of islets, first reported by Lim and Sun [110], of
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encapsulation devices from the macro- to nano-scale has shown that islets encapsulated in
APA microcapsules survived well and resulted in long term normoglycemia [111, 112].
Figure 2.3 shows the protocols of islets microencapsulation with APA [11].

Figure 2. 3 Microencapsulation of islets with alginate-polylysine [111].

The shortcomings of APA microcapsules are that they are immunogenic and
highly bio-incompatible due to the PLL coating. PLL coating degrades over time,
consequently leading to alginate matrix destabilization [113-115]. To overcome the
drawback associated with APA microcapsules, many people tried to crosslink alginate
with barium ions instead of calcium and without PLL to make barium alginate
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microcapsules [116]. Morch et al. [117] showed that the gelation ion Ba2+ rather than
Ca2+ yielded microcapsules of higher strength and stability when used with high G
alginate compared to APA microcapsules. Tuch et al. [118] is processing a product of
barium alginate microcapsules in phase I clinical study.

2.3.2.1.2.2 Agarose
Agarose microcapsules are made by gel formation in response to low
temperatures. Agarose microcapsules have been investigated as a stable and durable
immunoisolation membrane in human body [119-121]. Highly purified islets isolated
from non-obese diabetic (NOD) mice were microencapsulated in 5% agarose hydrogel as
a semi-permeable membrane to examine the feasibility of the immunoisolation. The size
range of agarose microcapsules was 100 to 400 µm. Islets encapsulated in agarose
microcapslues were transplanted into NOD spontaneously mice. Agarose microcapsules
were able to completely protect NOD islet isografts from autoimmune destruction [121].

2.3.2.1.3

Nano-scale encapsulation

The design of nano-scale encapsulation is similar to microcapsules. The
difference of nanoencapsulation compared to microencapsulation is to decrease the
thickness of the coating covering around the islets for forming the conformal coating. The
conformal coating can decrease the size of encapsulated islets, advance the passage of
nutrient, waste and insulin secretion between the implanted islets and extracellular matrix
(ECM), and improve the viability of islets. The ultimate goal of the BAP is the
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immunoisolation property for protecting implanted islets from host immune systems,
while at the same time still keeping cell function and viability as well as normal islets.
Islets with a thin coating can be transplanted into the liver through the portal veins. In the
following, some new techniques for surface modification of islets will be introduced.

2.3.2.1.3.1 Polymers coating
Surface modification with ultra thin polymer membranes was reported by
chemically treating red blood cells to enclose surface antigen [122-124]. The surface
modification of islets with thin polymer membranes has been investigated by using
amphiphilic polymers, such as PEG-conjugated phospholipid (PEG-lipid), polyvinyl
alcohol (PVA, carrying long alkyl chains), and cationic polymers like poly
(ethyleneimine) (PEI) (Fig. 2.4) [125].
PEI as a cationic polymer can be coated on the islets surface by the layer-by-layer
method. The negatively charged cell surface bond with positively charged PEI, and then
the surface is further exposed to a negatively charged polymer to form a layer-by-layer
membrane based on the electrostatic binding theory [126].
The PEG chain can be anchored to the cell surface through the hydrophobic
portion of the PEG-lipid and incorporated into the lipid layer of the cell membrane [127129]. The thickness of the PEG layer on the cell surface is several nanometers, which
depends on the molecular weight of the PEG used [130]. The layer-by-layer method was
used to improve the stability of the PEG-lipid membrane on the cell surface. Functional
groups, such as biotin and maleimide, can be easily bonded to the end of the PEG chain
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of PEG-lipid [131, 132]. Teramura et al. [127] formed a layer-by-layer membrane of
PVA with thiol groups on a PEG-lipid with a maleimide group on the surface of islets
using the reaction between the thiol and maleimide groups. Moreover, PEG carrying an
N-hydroxyl-succinimidyl ester (NHS), activated ester group at one end was employed to
react with an amino group of the membrane proteins or collagen layer on the islet surface
[133, 134]. Byun’s group reported that normoglycemia was maintained for 1 year after
islets with a PEG-NHS modified surface were transplanted into recipient rats treated with
low dose of cyclosporine A [135, 136].

Figure 2. 4 Modification of cell surface with synthetic polymers: Covalent bonding,
hydrophobic interaction, electrostatic interaction, and the layer-by-layer method [125].
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2.3.2.1.3.2 Living cells coating

Figure 2. 5 Encapsulation of islets with living cells. (A) Hamster islets modified with
polyA20-PEG-lipid were treated with (a-1, FITC) FITC-labeled polyT20. (a-2) Naked
islets were treated with FITC-labeled polyT20. (B) Attachment of polyT20-PEG-lipid
modified GFP-HEK cells onto the surface of polyA20-PEG-lipid modified hamster islets.
An islet was observed by a confocal laser scanning microscope for (b-1, GFP) and a
phase contrast microscope (b-2). (C) GFP-HEK cells-immobilized islets were cultured
for 1, 3, and 5 days. Islets were observed by a phase contrast microscope (left panels) and
a confocal laser scanning microscope (right panels, GFP). Scale bars: 200 μm [140].

The new approach for surface modification of islets is living cells coating. Living
cells coating can improve the histocompatibility and blood compatibility, inhibit the graft
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rejection, and decease the destruction of implanted islets resulting from blood-mediated
inflammatory reactions. Pollok et al. [137] first attempted to microencapsulate rat islets
with a porcine chondrycyte membrane. Kim et al. [138] also macroencapsulated islets
with a chondrocyte membrane using the cell sheet engineering technique. Teramura et al.
[139, 140] used amphiphilic PEG-lipid and the biotin/streptavidin reaction to immobilize
HEK293 cells on the surface of islets (Figure 2.5). The function of insulin secretion was
well maintained after HEK293 cell encapsulation.

2.3.2.2 Islets functional modification
There has been growing attention in modifying islets with growth factors or
peptides to confer biological functionality.

2.3.2.2.1

Growth factors

In pancreatic islet transplantation, early revascularization is necessary for longterm graft function. Cabric et al. [141] has shown in in vitro and in vivo models that
modification with surface-attached heparin protected the islets from acute attack by the
innate immune system of the blood following intraportal islet transplantation.
Furthermore, vascular endothelial growth factor-A was conjugated to heparin as a means
of attracting endothelial cells to induce angiogenesis and revascularization to improve
islet engraftment in pancreatic islet transplantation.
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2.3.2.2.2

Peptides

Islet transplantation has the potential to treat type I diabetes; however, its
widespread clinical application is limited by the massive apoptotic cell death and poor
revascularization of transplanted islet grafts. Wu et al. [142] constructed a surfacemodified adenoviral vector with Arg-Gly-Asp (RGD) sequences encoding a human Xlinked inhibitor of apoptosis and hepatocyte growth factor (RGD-Adv-hHGF-hXIAP). In
vivo transduction of islets with RGD-Adv-hHGF-hXIAP decreased apoptotic islet cell
death, improved islet revascularization, and eventually might improve the outcome of
human islet transplantation.
2.3.3

Beta cells transplantation
Within islets, there are five endocrine cell types that work as a micro-organ to

maintain glucose homeostasis. Insulin is normally produced in and secreted by the β-cells
of islets. Because of difficulties associated with the use of primary islets, such as limited
human pancreas donation, the risk of zoonosis in case of an animal source, low isolation
yield, and preservation [143], the β-cells replacement through cellular transplantation to
replace primary islets has the promise of providing a long-term cure for type 1 diabetes.
To achieve this goal, β-cells have been transplanted with hollow fibers, diffusion
chambers, hydrogels, macrocapsules, or composites of them. These carriers have been
proposed to protect cells from attack by the host immune system and to enhance β-cell
survival and function in vivo.
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2.3.3.1 Hollow fibers
The blood perfusion hollow fiber is similar to dialysis. Blood is perfused in the
hollow fiber and β-cells are placed around the fibers. The advantage of the hollow fibers
device is to enhance the diffusive exchange rate between β-cells and blood [144]. For
example, the poly (ethylene-co-vinyl alcohol) (EVAL) hollow fibers were designed to
develop a new type of bioartificial pancreas [100]. As Figure 2.6 shows, the device
includes EVAL hollow fibers and poly (amino unrethane) coated, non-woven poly
(tetrafluoroethylene) (PTFE) fabrics. Beta cells attached to the surface of the PTFE
fabric, but not to the surface of the EVAL hollow fibers, allowing nutrient and oxygen
exchange between blood flowing inside the fibers and cells outside.

Figure 2. 6 Construction of a bioartificial pancreas module. (A) A piece of non-woven
fabric with a backing of rayon cloth was covered with 550 hollow fibers. (B) The fibers
and cloth were rolled together and the spaces between the hollow fibers were sealed with
urethane, and the roll was inserted into a polycarbonate casing with dimensions as shown
[100].
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2.3.3.2 Diffusion chambers
The macroencapsultion of β-cells includes a diffusion chamber in which β-cells
are contained in a space surrounded by a semi-permeable membrane [145]. The
advantage is that this chamber can be easily implanted into an intraperitoneal or
subcutaneous space and is also easy to remove [146, 147]. Typically, β-cells are
entrapped between two semi-permeable membranes placed on both sides of a ring-like
structure. A PTFE device was used to encapsulate human fetal pancreatic islet-like cell
clusters and transplanted into immunodeficient mice. After one month, encapsulated cell
clusters survived, replicated, and acquired a level of glucose responsive insulin secretion
sufficient to ameliorate hyperglycemia in diabetic mice [145, 148, 149].
Alumina biocapsule can be regarded as a particular type of diffusion chamber.
These devices [150-152] have robust membranes and their pore size and pore size
distribution can be easily controlled. The capsules were fabricated out of aluminum and
aluminum oxide using a two-step anodization procedure, and the pore size is about 72
nm. PEG immobilization on the alumina surface was achieved using a covalent coupling
agent silicon tetrachloride. In vivo study has demonstrated that implantation of these
capsules into the peritoneal cavity of rats induces a transient inflammatory response, and
that PEG was useful in minimizing the host response to the material.

2.3.3.3 Hydrogels
Encapsulation of β-cells within hydrogels is a potential transplantation therapy
independent of immune suppression for type 1 diabetes. Hydrogels as semi-permeable
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barriers allow the passage of insulin, nutrients and waste, while preventing cell-cell
contact between host immune cells and encapsulated β-cells and the penetration of large
immune cell-secreted antibodies. Several hydrogels have been developed toward this
application, such as PEG, agarose [153, 154], collagen-alginate [155], collagen-gelatin
[156, 157], and polyurethane-polyvinylpyrrolidone [158].

2.3.3.3.1

PEG hydrogels

PEG hydrogels provide a highly biocompatible niche for β-cells because of their
high water content, simple chemical modifications to incorporate biomolecules, and
limited immunogenicity in vivo [159-162]. A photopolymerization PEG hydrogels was
developed to test the effects of microenvironmental culture parameters on survival and
function of encapsulated β-cells [163]. The results showed that the different hydrogel
crosslinking density did not affect β-cells survival, and encapsulated β-cells transplanted
into diabetic mice decreased blood glucose levels to normal levels. Furthermore, different
matrix proteins, including collagen type I and IV, fibrinogen, fibronectin, laminin, and
vitronectin, were mixed into PEG hydrogels to investigate the effects of matrix proteins
on β-cells survival and function [164]. Apoptosis in encapsulated β-cells was less in the
presence of each matrix protein, suggesting the ability of individual matrix interactions to
prevent matrix signaling-related apoptosis (anoikis). Beta cell function in hydrogels
presenting both collagen type IV and laminin revealed synergistic interactions.
PEG hydrogels provide a blank platform on which defined bioactive/functional
motifs, such as peptides, can be easily incorporated without significantly affecting the
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bulk material properties [165]. Cell-adhesive peptides (e.g., RGD, IKVAV, YIGSR, etc.)
have been routinely conjugated within synthetic PEG hydrogel networks to promote
survival of β-cells [166, 167]. The different peptides conjugated on PEG hydrogels and
their effects on behaviors of β-cells are given in Table 2.2.
However, encapsulation with passive barrier PEG alone is generally insufficient
to protect β-cells from rejection, because small cytotoxic molecules produced by
activated T cells can diffuse readily into the capsule and mediate allograft death. As a
means to provide bioactive protection for polymeric encapsulation devices, Hume et al.
[168, 169] investigated a functionalized polymeric coating that mimics a natural T cell
regulation pathway. Anti-Fas antibodies capable of inducing T cell apoptosis were
covalently incorporated PEG hydrogels. Figure 2.7 shows how the functionalized PEG
was formed. Glucose oxidase-initiated dip coatings enabled the rapid formation of
uniform PEG-based coatings which incorporate anti-Fas antibody on the surfaces of PEG
hydrogels.
Table 2. 2 Peptide conjugated PEG hydrogels for β-cells encapsulation.
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Figure 2. 7 Schematic illustrating the formation of polymer coatings initiated by glucose
oxidase (GOx). (A) Cell-laden PEG hydrogels are swollen in a glucose-containing media
and then (B) dipped into a pre-polymer solution containing acryl-PEG, GOx, Fe2+, and
thiolated signaling molecules. Glucose diffuses out of the gel, reacts with GOx and
initiates polymerization at the surface of the hydrogel. (C) Reactive coating results in
conformal PEG layers. (D) Confocal micrograph of PEG hydrogel (green) with GOx
mediated polymer coating (red). Scale: 200 µm [169].
2.3.3.3.2

Glucose-responsive hydrogels

A glucose-responsive hydrogel including concanavalin A was suggested to
control the release insulin through β-cells entrapped in hydrogels [170, 171]. At low
glucose concentrations, the materials were in a gel state that exhibited low insulin
permeability, while at high glucose levels, the materials became a solution that exhibited
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a higher permeability to insulin. Thus, at low glucose concentrations, a higher fraction of
the insulin secreted by cells accumulated within the construct, and the insulin release rate
was relatively low. When the construct was exposed to high glucose, the material became
a more permeable solution, and the insulin release rate form the construct was higher.

2.3.3.3.3

Collagen-alginate hydrogels

Lee et al. [155] formed islets cell spheroids by using concave wells, and then
encapsulated spheroids into alginate and collagen-alginate composite (CAC) hydrogels.
Figure 2.8 shows the fabrication process. Alginate or CAC was covered on a concave
microwell model containing islets spheroids, and CaCl2 solution was diffused through a
nano-porous dialysis membrane to achieve uniform polymerization, forming convex
structures. The in vitro and in vivo data showed that the collagen-alginate
microencapsulation method enhanced the viability and function of islet spheroids, and
protected these spheroids from immune attack.
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Figure 2. 8 Schematic depiction of the in vitro cultivation of dispersed islet single cells,
formation of islet cell-spheroids using concave microwell arrays, and the process of
spheroids encapsulation within collagen-alginate composite [155].

2.3.3.4 Microcapsules
Encapsulation of β-cells in micro scale capsules has been suggested as an
alternative approach compared to macroencapsulation. Microencapsulation increases
surface-area-to-volume ratio, which enhances transport properties. The most popular
biomaterials used to encapsulate β-cells are alginate and agarose.
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2.3.3.4.1

Alginate

Traditional

microencapsulation

involves

entrapping

β-cells

in

a

alginate/polylysine capsule [172-174]. For monitoring the fate of transplanted β-cells,
gold nanoparticles treated with dithiolated diethylenetriamine-pentaacetic acid and
gadolinium chelates (GG) were co-encapsulated in alginate capsules [173, 174]. Figure
2.9 shows a three-dimensional structure of an alginate/polylysine microspheroid
encapsulating β-cells and GG. The micro spheroid allowed diffusion of oxygen, nutrients,
glucose, and insulin, and blocked the passage of immune cells and antibodies. Gold
nanoparticles enabled multimodal cellular imaging of transplanted islet cells such as
magnetic

resonance

imaging,

micro-computed

tomography,

and

40-MHz

ultrasonography.

Figure 2. 9 Three-dimensional structure of alginate/polylysine microspheroid
encapsulating β-cells and gadolinium chelates [174].
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To improve the passage of oxygen, nutrients, glucose, and insulin, some groups tried to
decrease the size of microcapsules through conformal encapsulation [175] or nanofilm
encapsulation technique [176]. An electrostatic layer-by-layer (LBL) technology was
developed to form a chitosan/alginate nanocoating film on the surface of MIN-6 β-cell
clusters [176]. A phosphorylcholine-modified chondroitin-4-sulfate layer was coated on
the surface of β-cell microcapsules to reduce nonspecific protein adsorption of the
chitosan/alginate nanofilm and to enhance biocompatibility of the nanocoating.
For fabricating homogenous and asymmetric microencapsulation, Dang et al.
[177] developed a new fabrication method by using micromolding systems. The rat
insulinoma cell line (INS-1) was used and encapsulated with alginate in a polypropylene
mesh mold. After cross-linking by CaCl2, Alginate hydrogel microcapsules were formed.
Beta cells encapsulated in alginate microcapsules maintained desirable viability and
preserved their ability to proliferate and secrete insulin in a glucose-responsive manner.

2.3.3.4.2

Poly (N-isopropylacrylamide)

Liu et al. [178] reported that the encapsulation of MIN6 cells was investigated by
using thermally induced gelable materials based on poly (N-isopropylacrylamide). A
vertical co-extrusion was used and a 37 ºC collection bath was settled with a paraffin
layer above media. The size of microcapsules ranged from 500 to 900 µm. Encapsulated
β-cells exhibited high viability after 5 days and a static glucose challenge showed
glucose-dependent insulin secretion.
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2.3.3.5 Composites
2.3.3.5.1

Hollow fibers/microcapsules

To start, people encapsulated single β-cells into microcapsules to fabricate
artificial islets, and then entrapped artificial islets in chambers of hydrogels for in vivo
transplantation. A blood perfusion composite was fabricated based on βTC3/agarose
microspheres encapsulated in a polysulfone hollow fiber [179]. The in vitro results
showed that encapsulated βTC3 exhibited high viability and functionality compared to
islets. Yang et al. [180] designed a bioartificial pancreas based on a calcium phosphate
cement chamber used to encapsulate β-cells/agarose microspheres. In vitro results
exhibited that encapsulated β-cells had normal viability, cell survival and insulin
secretion. In vivo study showed that the bioartificial pancreas implanted in the bone
marrow cavity for the spontaneous diabetic was effective [181, 182].

2.3.3.5.2
For

Hydrogels/microcapsules
early

research,

β-cells/agarose

microspheres

were

entrapped

in

chitosan/gelatin hydrogel as an immunoisolative matrix [156]. Microencapsulated βcells/agarose microspheres kept functional activity and secreted insulin continually for 60
days in vitro. Chitosan/gelation hydrogels revealed cytoprotective effects against
cytokine-mediated cytoxicity. After being injected with chitosan/gelatin containing βcells/agarose microspheres at the subcutaneous tissue, the non-fasting blood glucose
concentrations of diabetic rats injected was decreased to euglycemic status albeit
hyperglycemia within 10 days and was maintained at less than 200 mg/dL for 25 days
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[157].

2.3.4

Cell sources for β-cell regeneration
Although transplantation of human islets has the potential to treat type 1 diabetes,

the limitations of donors and immunosuppression therapy restrict the application. Thus,
alternative sources of β-cells need to be found. There have been two major approaches
for β-cell regeneration in recent years: the in vitro generation of renewable β-cells
suitable for transplantation and the in vivo regeneration of β-cells from undefined
progenitors or adult stem cells.

2.3.4.1 In vitro generation of β-cells
As for in vitro regeneration, β-cells can be obtained from different sources, such
as embryonic stem cells (ESCs), induced pluripotent stem cells, and so on. The details
about how to regenerate β-cells from these stem cells have been thoroughly investigated
and can be referred to reviews: [183-185]. However, the conditions under which the
pancreatic stem cells mature into insulin-producing cells still need to be well defined. Of
the safety concerns associated with the transplantation of stem cell-derived tissues, one
main issue is tumorigenicity. Moreover, the use of immunosuppressive drug regimens
concurrent with the use of allogenic or xenogenic cells for transplantation will need to be
elucidated, tested and standardized. At present, the effect of immunosuppressive drugs on
the insulin-producing capacity of pancreatic stem cells is unknown.
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For in vitro regeneration, various types of bioengineering approaches have been
used to offer a microenvironment mimicking the niche. The niche plays an important role
in promoting cell-to-cell interaction, cell proliferation and differentiation into specific
lineages, as well as tissue organization [186, 187]. The study of β-cell regeneration based
on bioengineering approaches is mainly focused on the cell sources of embryonic stem
cells, embryonic pancreatic precursor cells, fetal pancreatic precursor cells, and
mesenchymal stem cells [188].

2.3.4.1.1

Embryonic stem cells (ESCs)

Embryonic stem cells have been investigated as a potential renewable source of
cells in replacement therapies for type 1 diabetes. The five step protocol for in vitro
generation of pancreatic cells from ESCs was reported in which cells were transitioned
through mesendoerm, definitive endoderm, foregut endoderm, pancreatic endoderm, and
the endocrine precursoe stage, until mature β-cells were obtained [189].
Calcium alginate microspheres were used to encapsulate human embryonic stem
cells (hESCs). The three dimensional model promoted cellular interactions. These
encapsulated hESCs were differentiated to definitive endoderm [190]. Hoof et al. [191]
tried to adjust the differentiation of hESCs into pancreatic endoderm through culturing
hESCs in glass cover slips patterned by the covalent microcontact-printing of laminin in
circular patches of 120 µm in diameter. These hESCs formed clusters and differentiated
to pancreatic endoderm-like cells. Moreover, mouse ESCs (mESCs) were encapsulated in
collagen gel to form a three dimensional ES cell pancreatic differentiation system. The
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encapsulated mESCs can assemble into an islet-like tissue structure. Nearly 50-60% of
the cells formed cell clusters expressed insulin.

2.3.4.1.2

Pancreatic precursor cells

Pancreatic precursor cells are isolated from the developing pancreatic bud. These
cells have been investigated as an unlimited source of β-cells, as they have been directed
down the early stages of pancreatic development but remain proliferative and have the
innate ability to differentiate into insulin-producing β-cells [192].
Previous research has shown that embryonic pancreatic precursor cells
encapsulated in unmodified PEG selectively after 7 days differentiated into pancreatic βcells which were immature and unable to release insulin in response to changes in media
glucose concentration [193]. For functional β-cell regeneration, collagen type 1 was
entrapped in a PEG culture system [194]. Collagen type 1, which promotes mature cell
viability and function, entrapped in PEG hydrogels could improve the differentiation of
precursor cell clusters to form mature, glucose-responsive, islet-like structures. Concerted
differentiation of pancreatic precursor cell aggregates into functionally mature islet-like
clusters can be achieved in PEG culture system by blocking cell contact-mediated Notch
signaling with a gamma-secretase inhibitor [195].
For

in

vivo

regeneration,

porcine

neonatal

pancreatic

cell

clusters

microencapsulated in barium alginate were transplanted into streptozotocin-induced
diabetic severe combined immunodeficient mice [196, 197]. These results exhibited that
cells/alginate microspheres transplanted into immunocompetent mice could differentiate
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into β-cells and reverse high blood glucose levels without immunosuppression for above
20 weeks. Montanucci et al. [198] encapsulated human islet-derived stem/precursor cells
within alginate microspheres for transplantation. Alginate-based microspheres acted as
three-dimensional niches to promote post-transplant precursor differentiation and
acquisition of stem cells into immonodeficient (SCID) mice.

2.3.4.2 In vivo regeneration of β-cells
Recently, in vivo neogenesis of β-cells from pancreatic and non-pancreatic cells
has been reported in adults. Evidence to support the presence in adult pancreas of a
population of undifferentiated stem/progenitor cells that can give rise to all pancreatic
cell types has still not been found. It has been shown that replication of differentiated βcells contributed to new β-cells during normal adult life. However, neogenesis of islets
also occurred during normal development (at least during the first month) and in response
to physical and physiological stress. Recently, Xu et al. [199] demonstrated that the
neogenesis of β-cells accompanied the induction of Ngn3-expressing endocrine
progenitors in the ductal lining in the regenerating portion but not in the non-injured
pancreas. Also, the liver represents an attractive in vivo source for generating β-cells due
to its related developmental origin to the pancreas and its ease of genetic and surgical
manipulation.
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2.4 Conclusion remarks
Although various delivery systems such as hydrogels and microspheres have
proved to be effective for insulin release, and non-injectable methods of insulin delivery
have resulted in some clinical researches [200], frequent blood glucose monitoring and
multiple daily insulin injections are still the common treatment for type 1 diabetes. This
treatment can not provide sustained release and the insulin amount is not finely tuned to
glycemia, so it can not prevent long-term complications such as cardiovascular disease,
retinopathy, and nephropathy [201]. The development of a fully automated glucoseresponsive device is the ultimate aim for type 1 diabetes treatment.
Pancreatic islet transplantation is a potential approach for patients not only to
avoid insulin injection, but also to avoid complications. The limitations of islet
transplantation are the significant shortage of donor pancreases and the long-term
immunosuppressive therapy after transplantation. The development of a bioartificial
pancreas based on bioengineering approaches has been considered to solve these
problems.
The bioartificial pancreas based on bioengineering strategies protects transplanted
islets from the immune system, but the next problem is how to improve long-term
survival and function of transplanted pancreatic islets. It would be beneficial to mimic the
β-cell interactions within its native environment and create this islet niche as best as
possible in a carrier or capsule. The environment would include not only the islets, but
accessory cells, proteins, and possibly local immunosuppression housed within a
biocompatible materials. This microenvironment can also provide an alternative for the
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regenerative cell-based therapy, so that other sources of β-cells can find their way to
clinical therapy.
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CHAPTER THREE
3. DEVELOPING HYDROGELS SYSTEMS FOR THE FORMATION OF
ISLETS OF LANGERHAM FROM SINGLE ΒETA-CELLS
3.1 Introduction
The applications of cell and tissue replacement therapies are usually limited by
the lack of appropriate delivery platform for cells and engineered tissues. Successfully
designed biomaterials systems for cell replacement therapies often intergrate multiple
factors, such as cell-extracellular matrix (ECM) interactions, biomolecules (growth
factors, peptides, cytokines, etc.), and cell-cell interactions [1, 2]. A successful design
will further improve the spatial and temporal presentation of these factors to the
encapsulated cells [3]. Hydrogels are important biomaterials for cell encapsulation and
delivery, which can offer a physical barrier or “immuno-isolation” between the host
tissue and encapsulated cells. Poly (ethylene glycol) (PEG) hydrogels are often
considered advantageous for engineering such synthetic microenvironments used for cell
delivery. PEG hydrogels present unique advantages for cell delivery because of their high
water content and quick diffusion characteristics. Further, the nonfouling properties of
PEG hydrogels provide a “blank slate” on which defined bioactive/functional motifs,
such as peptides and proteins, can be easily incorporated without significantly affecting
the bulk material properties [4, 5].
The peptide-functionalized PEG hydrogels mimic aspects of the ECM to support
the survival and function of encapsulated cells. The specific amino acid sequences
present at the binding sites, which include RGD (Arg-Gly-Asp), IKVAV (Ile-Lys-Val-

Ala-Val), YIGSR (Tyr-Ile-Gly-Ser-Arg), RYVVLPR (Arg-Tyr-Val-Val-Leu-Pro-Arg),
and RNIAEIIKDI (Arg-Asn-Ile-Ala-Glu-Ile-Ile-Lys-Asp-Ile), have been identified as
being involved in cell-receptor interactions. RGD and IKVAV are present on α laminin
chain, whereas YIGSR is found on the β laminin chain [6-8]. Peptides, when compared to
whole proteins, are more stable, easily synthesized, and are less likely to exhibit steric
hindrance after biomaterial modification.
Many studies have been reported to encapsulate islets or insulin-producing β-cells
in PEG hydrogels for cell transplantation. To date, the design of an islets or insulinproducing β-cells delivery barrier has been largely focused on optimizing material
biocompatibility and tailoring material properties for cell encapsulation. Few strategies
use material functionalities to mimic or promote cell-cell interactions in a threedimensional (3D) microenvironment [9]. Cell-cell interactions are important for
maintaining β-cells survival and functionality [10]. In this study, we have developed a
series of functionalized hydrogels based on in situ gelable, non-immunogenic material,
including multi-arm (4-arm) thiolated PEG and poly (ethylene glycol) tetra-acrylate
(PEGTA), focused on promoting the survival and functionaility of encapsulated
pancreatic β-cells (MIN6) in 3D. PEG hydrogels were designed to encapsulate β-cells for
forming clusters from single cells as islets, which will improve the cell-cell interactions.
Using the peptide incorporation technique, PEG hydrogels were synthesized containing
peptide tethers of IKVAV, YIGSR, RGD. Individual MIN6 β-cells were encapsulated in
peptide-containing hydrogels, and cell survival and glucose-stimulated insulin secretion
were observed with culture time.
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The central hypothesis for this study is that PEG hydrogels can be designed for
the formation of artificial islets to maintain β-cells survival and functionality as a
biomimetic cell delivery platform. Engineering PEG hydrogels with different peptides in
3D culture systems can improve the viability and functionality of β-cells and promote
cell-cell interactions.

3.2 Materials and methods
3.2.1

Materials
4-arm poly (ethylene glycol) (MW, 10kDa) and poly (ethylene glycol)

tetraacrylate (MW, 10kDa, PEGTA) was obtained from Creative PEGWorks (Winston
Salem, NC). Three types of adhesive peptides, CSRARKQAASIKVAVSADR (Cys-SerArg-Ala-Arg-Lys-Gln-Ala-Ala-Ser-Ile-Lys-Val-Ala-Val-Ser-Ala-Asp-Arg), GRGDSPC
(Gly-Arg-Gly-Asp-Ser-Pro-Cys), and CDPGYIGSR (Cys-Asp-Pro-Gly-Tyr-Ile-Gly-SerArg), were purchased from American Peptide Company (Sunnyvale, CA). Cell culture
reagents and supplements were obtained from Invitrogen (Carlsbad, CA). LIVE/DEAD
viability kit was obtained from Molecular Probes (Eugene, OR). Insulin enzyme linked
immunosorbent assay (ELISA) kit was obtained from Millipore (Billerica, MA). All
other reagents were purchased from Sigma Aldrich (St. Louis, MO).

3.2.2

Synthesis of thiolated multi-arm PEG
Multi-arm PEG was chain-end thiolated by esterification reaction with

thioglycolic acid (TGA) using p-toluenesufonic acid as a catalyzer [11]. Briefly, 5 g of
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multiarm PEG (4-arm PEG), 0.4 g TGA, and 5 mg p-toluenesufonic acid, were added to
100 mL of toluene preheated to 120 °C. The reaction proceeded for 24 hrs under nitrogen
atmosphere. The thiolated prepolymer was purified by precipitation into anhydrous ether
(200 mL) at 4 °C. This sequence was repeated three times using dichloromethane as a
solvent. The product was then dried under vacuum at room temperature for 3 days.

3.2.3

Preparation of hydrogels
PEGTA and 4-arm thiolated PEG stock solutions (10%, w/v) were prepared by

dissolving powders in phosphate buffered saline (PBS), respectively. To elucidate the
influence of polymer concentration on hydrogel properties, PEGTA solutions of different
concentrations (1.5%, 2%, 2.5%, 5%, 7.5%, and 10%) were mixed with 4-arm thiolated
PEG of different concentrations (1.5%, 2%, 2.5%, 5%, 7.5%, and 10%) in a ratio of 1:1,
respectively. Moreover, a 5% PEGTA solution mixed with a 5% 4-arm thiolated PEG
aqueous solution in specific volume ratios (2:10, 3:9, 4:8, 6:6, 8:4, 9:3, and 10:2), and
another 2.5% PEGTA solution mixed with a 2.5% 4-arm thiolated PEG aqueous solution
in specific volume ratios (3:9, 6:6, and 9:3), were also used to determine the effect of
feed ratio on the properties of hydrogels formed.

3.2.4

Rheological characterization of hydrogels
For rheological study, hydrogel solutions of PEGTA and 4-arm thiolated PEG

were mixed on the steel plate geometry and inspected by oscillatory shear rheometry
immediately [12, 13]. An AR1000 rheometer (TA Instruments Inc.) with standard
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geometry of 40 mm diameter was used for the rheological characterization of all
hydrogels samples. The test methods employed were oscillatory time sweep, frequency
sweep and stress sweep. The time sweep was performed to monitor the in situ gelation of
the hydrogel solutions at 37 °C. The test, which was operated at constant frequency (1 Hz)
and strain (5%) and terminated after 60 minutes, recorded the temporal evolution of shear
storage modulus (G’) and the shear loss modulus (G’’). The stress sweep was set up by
holding the temperature 37 °C and constant frequency (1 Hz) while increasing the stress
level from 1 to 10 Pa. The applied range of 1-10 Pa was found to be safe-for-use from a
prior experiment where we determined the linear viscoelastic region (LVR) profiles of
the hydrogels by shearing them until structure breakdown. We also subjected hydrogels
to a frequency sweep at 50% of their respective ultimate stress levels. At this fixed shear
stress and temperature (37 °C), the oscillatory frequency was increased from 0.1 to 100
Hz and the G’ was recorded.
Young’s modulus, E, can be evaluated by E = 2G (1+γ). When a material can be
assumed to be incompressible, its Poisson’s ratio, γ, approaches 0.5 and this relationship
approaches E = 3G. This assumption for hydrogels is supported by a research showing
that n for polyacrylamide hydrogels is nearly 0.5, and these hydrogels typically used
under very low strain. This relationship between E and G then provides a useful tool for
comparing mechanical properties of substrates and tissues that have been determined
using other methods of measurement.
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3.2.5

Swelling of hydrogels
Hydrogels of different concentrations (1.5%, 2%, 2.5%, 5%, 7.5%, and 10%), 5%

hydrogels with different ratios (2:10, 3:9, 4:8, 6:6, 8:4, 9:3, and 10:2), and 2.5%
hydrogels in specific volume ratios (3:9, 6:6, and 9:3), were used to determine the effects
of concentrations and feed ratios on the swelling properties of hydrogels. To characterize
the swelling behavior of the hydrogels, they were weighed immediately after preparation.
Hydrogels were placed in 5 mL of PBS solution at 37 °C and allowed to swell. Weights
were taken every 24 hours for the next 30 days. Fresh PBS, previously equilibrated at 37
°C, was replaced every 24 hours at the time of measurement. The swelling ratio was
calculated by dividing the weight of the hydrogels at equilibrium swelling by their weight
after gelation.

3.2.6

Peptide conjugated to hydrogels
Different peptides, such as IKVAV, YIGSR, and RGD of different concentrations

(1 and 0.2 mM) were conjugated to PEG hydrogels through addition reaction of peptide
cys thiols onto the ends of a PEGTA crosslinker as described before. Briefly, peptides
containing stock solutions (3 mM) were prepared in the PEGTA stock solution (5% w/w)
and stirring for 2 hrs at room temperature. Additional PEGTA solutions with lower
peptide concentrations (0.6mM) were prepared by diluting the stock solution with
peptide-free PEGDA solution (peptide: PEGTA=1:5). Then PEGTA solution containing
different concentrations of peptides was added to 4-arm thiolated PEG (5% w/w)
solutions at the ratio of 1:2 and mixed thoroughly to form hydrogels.
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3.2.7

Cell culture and encapsulation
Murine pancreatic β-cells of the MIN6 cell line were a kind gift from Dr. Bryan

Wolf at Children's Hospital of Philadelphia. MIN6 cells were cultured in Dulbecco's
Modified Eagle Medium (DMEM, 25 mM glucose) supplemented with 1% antibiotic and
antimycotic solution, 10% fetal bovine serum, and 80 µM of 2-mercaptoethanol at 37 ºC
in humid conditions with 5% CO2. The culture medium was exchanged every 2 days.
For encapsulation, MIN6 cells were mixed with PEG hydrogels or peptides
conjugated PEG hydrogels of different ratios before gel formation. To avoid cells
precipitating onto the surface of plate during the hydrogel formation, we coated the plate
with hydrogels overnight, then mixed MIN6 cells with hydrogel precursor solutions
(1×104 cells/well) and seeded on the top of pre-formed hydrogels. The culture medium
was changed every 2 days.

3.2.8

Cell viability
Viability of cells was examined using LIVE/DEAD viability kit, which is a two

color fluorescent assay based on differential permeability of live and dead cells and
allows preservation of the distinctive staining pattern for a couple of hours after
postfixation with 4% glutaraldehyde. Live cells were stained with green fluorescent
SYTO 10; and dead cells with compromised cell membranes were stained with red
fluorescent ethidium homodimer-2. The Leica TCS SP5 laser scanning confocal
microscope was used to capture the images of the LIVE/DEAD cell staining patterns.
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3.2.9

Glucose-stimulated insulin secretion
At designed time points, cultures were removed from encapsulation samples for

glucose-stimulated insulin secretion. Samples were first placed in a low glucose
concentration (1.1 mM) for 45 min, followed by incubation in a high glucose
concentration solution (16.7 mM) for 1 hr. The high glucose solutions were collected for
insulin measurement by ELISA insulin kit.

3.2.10 Statistical analysis
Data are shown as mean ± S.D. Statistical analyses were performed using oneway ANOVA (analysis of variance) followed by Tukey’s post tests and the paired t-test
where appropriate. A probability (p) value of <0.05 was considered statistically
significant.

3.3 Results
3.3.1

Hydrogel characterization

3.3.1.1 Mechanical properties of hydrogels
In this study, we have developed an in situ cross-linkable hydrogel based on 4arm thiolated PEG and PEGTA. Hydrogels formed at physiological conditions due to
conjugate addition reactions between thiols and acrylates. We achieved hydrogels with
different mechanical properties by adjusting PEG concentrations or the ratios of thiolated
PEG to PEGTA. Figure 3.1 shows the time sweep profiles of storage modulus (G’) for
the 10%, 7.5%, 5%, 2.5%, 2%, 1.5%, and 1% hydrogel networks within the small time
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frame (60 minutes). With increase of PEG concentrations G’ was increased accordingly
(Figure 3.1, inserted 1). 1% PEG solution could not form hydrogel at physiological
conditions. Higher PEG concentrations resulted in faster gelation (Figure 3.1, inserted 2).
The frequency and stress sweeps of hydrogels of various PEG concentrations were shown
in Figure 3.2 A and B, respectively.

Figure 3. 1 Evolution of shear storage moduli, (G’) of hydrogels as a function of time.
Inserted pictures: (1) G’ at 1 hr and (2) gelation time as a function of PEG concentrations.

Another way to obtain hydrogels of different stiffness is to change the ratios of
thiols to acrylates with the same PEG concentration. In 5% PEG solutions, the ratios of
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PEGTA to 4-arm thiolated PEG were adjusted as follows: 2:10, 3:9, 4:8, 6:6, 8:4, 9:3,
and 10:2. When the ratio of acrylates to thiols was kept at the stoichiometric balanced 1:1
(6:6), hydrogels formed with the largest G’ (4,000 Pa, Figure 3.3 A). In contrast, as to
ratios of 2:10 or 10:2, the biggest deviation to stoichiometric balance, PEG solutions
could not form hydrogels. The gelation of hydrogels with ratios (3:9, 4:8, 6:6, 8:4, and
9:3) occurred at about 10 minutes and the ratios showed no effects on gelation time. As
for 2.5% PEG solutions, hydrogels with acrylates to thiols 2:4, 3:3, and 4:2 formed within
30 minutes with G’ 75, 300, and 25 Pa, respectively (Figure 3.3B). 2.5% PEG solutions
with higher deviation to stoichiometric balance (1:3 and 3:1) could not form hydrogels,
either.

Figure 3. 2 (A) Frequency sweep of hydrogels of various PEG concentrations. (B)
Oscillatory stress sweep of hydrogels of various PEG concentrations.
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Figure 3. 3 Frequency sweep and oscillatory stress sweep of hydrogels of various ratios
of different concentrations of (A) 5% and (B) 2.5%.

3.3.1.2 Hydrogel swelling and degradation
The swelling of hydrogels was studied by incubating them at pH 7.4 and 37 °C.
Figure 3.4 A presents the dynamic swelling of the hydrogels as the function of
concentration (10%, 7.5%, 5%, 2.5%, 2%, and 1.5%). Hydrogels with increasing
concentrations (2.5%, 5%, 7.5%, and 10%) exhibited larger swell ratios, even though
2.5% and 1.5% showed no significant difference about their swelling ratios. All these
hydrogels with stoichiometric balanced ratios were stable with steadily increased weight
over the course of the study (3 weeks).

75

Figure 3.4 B and C shows the hydrogel swelling as the function of ratios of
PEGTA to 4-arm thiolated PEG at the concentration of 5% and 2.5%, receptively. With
the increase of deviation to stoichiometric balance from 6:6, 8:4 (4:8), to 9:3(3:9),
hydrogels with concentration of 5% exhibited larger swell ratios. Although hydrogels
with ratios of 4:8 exhibited larger swelling ratio than hydrogel of 8:4, both of them were
stable over 3 weeks. In contrast, hydrogels with the ratios of 3:9 and 9:3 degraded at 14
days and 20 days, respectively. When considering 2.5% PEG hydrogels, although both of
the hydrogels with ratios of 1:2 and 2:1 totally degraded at about 30 days, hydrogels with
ratio of PEGTA to 4-arm thiolated PEG 2:1 began to degrade earlier than hydrogels with
1:2 ratios (16 days as opposed to 26 days).

Figure 3. 4 Dynamic swelling of the hydrogels in PBS. (A) Degree swelling of hydrogels
as the function of concentration. (B and C) Degree swelling of hydrogels as the function
of ratios of PEGTA to 4arm PEGSH at the concentration of (B) 5% and (C) 2.5%.
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3.3.2

Effects of PEG hydrogels with different ratios on β-cell clusters formation
MIN6 cells were cultured in 5% PEG hydrogels with different ratios of 4-arm

thiolated PEG to PEGTA. The survival of encapsulated β-cells was determined by
LIVE/DEAD staining. In Figure 3.5, more than 90% of cells survived in all samples up to
7 days and there was no significant difference among all samples. MIN6 cells were
encapsulated as single cells, as Figure 3.5 shows, they can proliferate to form cell clusters
like artificial islets, especially in the specific samples of 1:2 and 1:3. Figure 3.6 illustrates
the quantity analysis of the size of cell clusters in PEG hydrogel with different ratios.
Larger sizes of cell clusters especially appeared in hydrogels of 1:2 and 1:3 at both the
day 4 and 7 (* P<0.05).

Figure 3. 5 LIVE/DEAD (Green/Red) staining of MIN6 cells 3D cultured in 5% PEG
hydrogels of different ratios of 4-arm thiolated PEG to PEGTA.
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Figure 3. 6 The size of artificial islets of MIN6 cells in 5% PEG hydrogels of different
ratios of 4-arm thiolated PEG to PEGTA (* P<0.05).

3.3.3

Effects of PEG hydrogels with different ratios on glucose-stimulated insulin
secretion
Figure 3.7 reports insulin secretion from MIN6 cells encapsulated in PEG

hydrogels with different ratios of thiolated PEG to PEGTA. On the first day, compared to
MIN6 cells cultured on the plate, MIN6 cells inside hydrogels appeared to have no
response to glucose stimulus. At the day 4, the cells encapsulated in the hydrogels of 1:2
and 1:3 secreted significantly higher amounts of insulin relative to those inside other
hydrogel samples (* P<0.05), and the amount of secreted insulin almost caught 2D
control group based on glucose stimulation. At the day 7, besides the cells inside the
specific hydrogel of 3:1, all the cells secreted similar amounts of insulin based on glucose
stimulus when compared to 2D culture.
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Figure 3. 7 Insulin release response to glucose from MIN6 cells cultured in 5% PEG
hydrogels of different ratios of 4-arm thiolated PEG to PEGTA at the day 1, 4 and 7 (*
P<0.05).

3.3.4

Effects of peptides on β-cell survival and clusters formation

Figure 3. 8 LIVE/DEAD (Green/Red) staining of MIN6 cells cultured in 5% PEG
hydrogels of 4-arm thiolated PEG to PEGTA at the ratio of 1:2 conjugated with different
peptides: IKVAV, RGD, and YIGSR at the day 4.
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MIN6 cells were cultured inside 5% PEG hydrogels with the ratio of thiolated
PEG to PEGTA at 1:2 conjugated with different concentrations of IKVAV, RGD and
YIGSR, respectively. As Figure 3.8 shown, more than 95% of cells survived in all
samples up to 7 days and there was no significant difference between all samples. As
described above, the cells in the hydrogels proliferated in the format of aggregates.
Peptides conjugated to hydrogels benefited aggreagate formation. Higher concentrations
of peptide resulted in larger sizes of cell clusters, especially in the hydrogels conjugated
with RGD and YIGSR (Figure 3.9, * P<0.05).

Figure 3. 9 The size of artificial islets of MIN6 cells cultured in 5% PEG hydrogels of 4arm thiolated PEG to PEGTA at the ratio of 1:2 conjugated with different peptides:
IKVAV, RGD, and YIGSR at the day 4 (* P<0.05).
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3.3.5

Effects of peptides on β-cell based on glucose-stimulated insulin secretion
Figure 3.10 shows insulin secretion from MIN6 cells encapsulated in PEG

hydrogels conjugated with different peptides. At day 4, using YIGSR and IKVAV, higher
amounts of pepides (1mM) conjugated to hydrogels resulted in larger amount of insulin
secretion from cells encapsulated in the gels (* P<0.05). These two peptides at 1 mM
benefited insulin secretion when compared to blank hydrogels. As to RGD, cells in the
hydrogels with RGD at 0.2 mM have secreted the similar amount of insulin compared to
those on 2D culture. Larger amount of RGD conjugation did not increase the insulin
secretion further.

Figure 3. 10 Insulin release response to glucose from MIN6 cells cultured in 5% PEG
hydrogels of different peptides at the day 4 (* P<0.05).
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3.4 Discussion
Developing bioactive hydrogels for 3D cell culture is an archetypal engineering
problem. The hydrogel concentration, mechanical property, adhesive ligand and growth
factor presentation, transport and degradation kinetics must be tuned to the given
culture’s needs a priori in a cytocompatible, reliable, and cost effective fashion. In this
chapter, through adjusting the concentrations of PEG and the ratios of 4-arm thiolated
PEG to PEGTA, we can achieve hydrogels with controllable mechanical properties
ranging from 1 to 10,000 Pa and adjustable degradation time from 2 weeks to several
months. MIN6 cells have been cultured inside hydrogels with different PEG
concentrations and the ratios of thilated 4-arm PEG to PEGTA. MIN6 cells expressed
very high viability in all the hydrogel samples. Another study has reported that MIN6
cells encapsulated in hydrogels formed from three PEGDM macromers of varying
molecular weights (Mn=4,000, 8,000, 10,000g/mol), showed similar viability [14]. The
optimal condition for the cells to form artificial islets in vitro is having the concentration
of PEG at 5% and the ratios of 4-arm thiolated PEG to PEGTA at 1:2 (or 1:3).
The cells inside the optimal hydrogels exhibited similar insulin secretion to cells
on 2D culture. Since the diffusion coefficient of agents, such as insulin, is determined by
the pore size of the hydrogel matrix, the average pore size of hydrogel network is
estimated based on rubber-elasticity theory according to equation 3.1[Assuming that all
chains contribute to the retraction force after deformation in a similar way (affine
deformation), neglecting end effects of single chains (all chains have fixed ends towards
an elastic background)] [15].
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Equation 3.1 Equation used to evaluate the mesh size of the gels [15].

Table 3. 1 Mesh size of hydrogels with various concentrations of PEG and different
ratios of 4 arm thiolated PEG to PEGTA.
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The mesh size of hydrogels calculated from their storage modulus is shown in
Table 3.1. The mesh sizes of hydrogels less than 5% are all over 10 nm. Since the size of
insulin is about 10 nm, the diffusion of insulin in the hydrogels is not inhibited when the
concentrations of hydrogels are less than 5%. There are different insulin screations from
cells in different hydrogels due to the cells which have been affected by the hydrogels but
not to physical inhibition of hydrogels themselves.
To further optimize our hydogel, different peptides, such as RGD, IKVAV,
YIGSR, have been conjugated to hydrogle matrix through the Machael reaction. These
specific amino acid sequences rather than whole proteins, are better suited for
biomaterials modification. As described before, they are more stable, easily synthesized,
and are less likely to exhibit steric hindrance after biomaterial modification [16].
Moreover, these ECM proteins are difficult to produce, have high batch-to-batch
variability, and may cause immune response if used in clinical applications. We have
found all of the peptides have benefited insulin secretion when compared to blank
hydrogels. Especially, RGD at 0.2 mM can significantly promote the insulin secretion,
similar to the 2D control group at the day 4.
Other investigators have reported similar results. In the absence of cell-cell and
cell-matrix contacts, encapsulated MIN6 β-cell survival diminished within one week;
however, in PEG hydrogel derivatives including the laminin sequences IKLLI and
IKVAV, encapsulated β-cells exhibited preserved viability, reduced apoptosis, and
increased insulin secretion. Interactions with the laminin sequences LRE, PDSGR, RGD,
and YIGSR contribute to improved viability, but insulin release from these samples was
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not statistically greater than that from controls. MIN6 β-cells were also encapsulated with
various concentrations of IKLLI and IKVAV (0.05-5.0mM), individually, and the peptide
combinations IKLLI-IKVAV, IKVAV-YIGSR, and PDSGR-YIGSR to explore
synergistic effects [9]. Moreover, bioactive GLP-1C was efficiently immobilized within
PEG hydrogels and did not alter the bulk hydrogel properties. The GLP-1 immobilized
PEG hydrogels enhanced the survival and insulin secretion of encapsulated islets [17].
To further enhance cell survival in the hydrogels, a polymerizable superoxide dismutase
was

incorporated

into

PEG

hydrogels

to

protect

encapsulated

cells

from

superoxidemediated damage, since superoxide and other small reactive oxygen species
can cause oxidative damage to donor tissue encapsulated within size exclusion barrier
materials [18]. Recently, Lin et al. has reported that when MIN6 cells were encapsulated
in PEG hydrogels, their survival and glucose responsiveness to insulin were highly
dependent on the cell-packing density. A minimum packing density of 107 cells/mL was
necessary to maintain the survival of encapsulated β-cells without the addition of material
functionalities. Thiolated EphA5-Fc receptor and ephrinA5-Fc ligand were conjugated
into PEG hydrogels via a thiol-acrylate photopolymerization to render an otherwise inert
PEG hydrogel bioactive. The biomimetic hydrogels provided crucial cell-cell
communication signals for dispersed β-cells and improved their survival and
proliferation. Together with the cell-adhesive peptide RGDS, the immobilized fusion
proteins (EphA5-Fc and ephrinA5-Fc) synergistically increased the survival of both
MIN6 β-cells and dissociated islet cells, both at a very low cell-packing density (< 2 ×
106 cells/mL) [10].
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3.5 Conclusion
In this chapter, we have optimized our hydrogel systems for MIN6 cells in 3D
culture. We have found that the optimal condition for the cells to form artificial islets in
vitro is the concentration of PEG at 5% and the ratios of 4-arm thiolated PEG to PEGTA
at 1:2 (or 1:3). Conjugated with RGD at 0.2 mM can significantly promote the insulin
secretion, similar to the 2D control group.
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CHAPTER FOUR
4

AUTOMATIC ROBOTIC FABRICATION OF BETA-CELL SPHEROIDS AND
MSC MICROENCAPSULATION IN A CORE-SHELL CONFIGURATION FOR
IMMUNOMODULATION

4.1 Introduction
In our body, most cells are organized in three-dimensional (3D) structures which
allow for cell-cell and cell-extracellular matrix interactions in a very complex
communication network of biochemical and mechanical signals. Knowing the cell
responses to environmental cues, including biochemical and mechanical signals, is
critical for the understanding development biology, disease progress, cancer biology and
treatment, and tissue regeneration. However, most in vitro cell studies in the literature are
from two-dimensional (2D) monolayer cultures. In 2D cultures, most cells lose tissue
specific properties; and the physiological and pathological studies based on 2D culture
may not reflect the signaling cascades in our body [1, 2]. To overcome the difficulties
and issues with 2D cultures, many three-dimensional 3D culture systems have been
tested, including organotypic tissue explants [3], cell seeded 3D scaffolds or hydrogels
[4], multicellular spheroids [2, 5], and so on.
Multicellular spheroids have advantages over the other methods due to its
simplicity, reproducibility, and similarity to physiological tissues and steer clear of the
mass transport issues associated with explants and scaffolds. These multicellular
spheroids have been widely used in many biological and medical applications, such as
screening new drug and biologics using human spheroids before clinical trial [6, 7],

understanding developmental biology, disease progress, cancer biology and treatment,
and tissue regeneration [8], and improving the survival of transplanted cells in vivo [5].
Although these advantages of spheroids have been widely recognized, it has been
difficult to scale up spheroid culture in a high-throughput manner. Preventing cells from
attaching to the culture ware substratum is the fundamental requirement for multicellular
spheroid generation. The general criteria for selecting a spheroid production method
include: production efficiency, spheroid size uniformity, possible damage or influence on
cellular physiology, convenience and suitability for subsequent applications. Traditional
fabrication methods for multicellular cell spheroids include hanging-drop [9, 10], roundbottomed well culture [11], non-adhesive surface, rotary bioreactor or spinner flasks [12],
microfabricated microstructures [13-16], and so on. However, none of these methods fits
the scalability criterion, either because spheroid shape and size can not be controlled
during the fabrication process or because the platform does not permit fabrication of
tissue spheroids in large number in a time efficient manner. The size and shape of the
spheroids are very important, since uncontrolled size and shape may induce mass
transport issues. Recently, a novel technique, high-throughput hydrogel microwells, has
been developed to achieve mass sphere production with easy spheroid handling and
diameter control [17, 18]. Mehesz and coworkers have combined this technique with
automated cell seeding for scalable robotic fabrication of uniform-sized tissue spheroids
[19].
The transplantation of islets of Langerhans is a potential option for curing type 1
diabetes, which can avoid the complications followed by major surgery compared to the
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whole pancreas transplantation. However, islets transplantation still faces the problems of
the long-term administration of immunosuppressive agents with severe side effects, and
the shortage of donor tissues [20-22]. To solve these issues, the immunoisolation of islets
with a semi-permeable membrane, and other cell sources for islets transplantation, has
been attempted. Immunoisolation of islets is a technology being excepted to overcome
the immune-mediated destruction of the donor tissues without requiring toxic
immunosuppression

agents

[23-25].

The

strategy

of

immunoisolation

means

encapsulating islets within a semi-permeable membrane made of biomaterials with good
biocompatibility. A variety of hydrogels have been applied to islet encapsulation.
Hydrogels protect the islets from immune system but still allow pro-inflammatory
cytokines and other effector molecules of low molecular weight to diffuse into the
capsules and affect the function and vitality of islets [26-28]. Control of islet graft
inflammation may be achieved by co-transplantation of islets with mesenchymal stem
cell (MSCs). These stromal cells are connective tissue derived stem cell with
immunomodulatory and regenerative properties. They also secrete anti-inflammatory
proteins and suppress the activity of various immune cells such as alloantigen activated T
and B lymphocytes.
Within islets, there are five endocrine cell types work as a micro-organ to
maintain glucose homeostasis. Insulin is normally produced in and secreted by the β-cells
of islets. Because of difficulties associated with the use of primary islets, such as limited
human pancreas donation, the risk of zoonosis in case of an animal source, low isolation
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yield, and preservation [29], the β-cells replacement through cellular transplantation to
replace primary islets has the promise of providing a long-term cure for type 1 diabetes.
In this study, we developed a fully robotic biofabrication method to produce
uniform size multi-cellular β-cells spheroids in large scale. Our method is the first one to
allow production of cell spheroids in large number and in a time-efficient manner. The
availability of this technique was assured. The size of uniform spheroids can be
manipulated by adjusting the seeding concentrations of cell suspensions. Uniform sized
multicellular β-cells spheroids can be coated with a thin layer of non-degradable hydrogel
for immunoisolation. In addition, the survival of spheroids of optimized size can be
further improved with a novel coating of multiple layers of MSCs to prevent graft
rejection. To prevent MSC migrate away from spheroids, another layer of non-degradable
hydrogel can be added. The function of β-cells in the spheroids with multiple layers
respond to glucose to release insulin was investigated by enzyme linked immunosorbent
assay.

4.2 Materials and Methods
4.2.1

Materials
Polytetrafluoroethylene (PTFE, Teflon) rods were obtained from McMaster-Carr

(Atlanta, GA). Methycellulose and Agarose were purchased from Sigma (St. Louis, MO).
LIVE/DEAD viability kit was purchased from Molecular Probes (Eugene, OR). Insulin
enzyme linked immunosorbent assay (ELISA) kit was obtained from Millipore (Billerica,
MA). Cell culture reagents and supplements were obtained from Invitrogen (Carlsbad,
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CA). Alexa Fluor-543 Phalloidin, 4', 6-Diamidino-2-Phenylindole, Dihydrochloride
(DAPI) was obtained from Molecular Probes (Eugene, OR). Human mitochondria
antibody (MAB1273) was purchased from Millipore (Billerica, MA). Rabbit anti-insulin
was purchased from Santa Cruz Biotechnology (Dallas, Texas). Fluorophore-conjugated
secondary antibodies were purchased from Jackson ImmunoResearch (West Grove, PA).
All other reagents were purchased from Sigma Aldrich (St. Louis, MO).

4.2.2

Cell culture
Rat pancreatic β-cells of the RIN-m cell line were obtained from ATCC (CRL-

2057). RIN-m cells were cultured in Roswell Park Memorial Institute (RPMI) 1640
medium supplemented with 10% fetal bovine serum at 37 ºC in humid conditions with
5% CO2. The culture medium was exchanged every 2 days.
Human bone marrow-derived mesenchymal stem cells (hMSCs) were obtained
from Sciencell (Carlsbad, CA). Human MSCs were plated in Modified Essential Medium
alpha (MEMα) supplemented with 10% fetal bovine serum. All the cells were incubated
at 37 ºC under 5% CO2 and used before passage 5 in this study. The culture medium was
exchanged every 2 days.

4.2.3

Βeta-cells spheroids fabrication
Βeta-cells spheroids with uniform sizes were fabricated using a robotic fabrication

system developed in our lab. Briefly, stamps with micronipple array were designed in
SolidWorks and fabricated using ultra-precision lathe. The automatic spheroid fabricator
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was built on a TT-C3-4040 robot (IAI Corporation, Shizuoka, Japan) with electric
triggered gripper to pick up the stamp and pipette tip uptake and ejection actuator to
handle liquid. Agarose solution (2% w/w) was prepared by built-in heating elements in
the robot platform. The robot was programmed to first add agarose solution to culture
dishes. Then the robot picked up the stamp with micronipple arrays on the bottom and
pressed on the agarose solution at room temperature for 2 minutes. Then the highly
uniform size microwells were formed in the agarose gel. Specific micro-mold, including
270 wells with the well diameter of 600 μm, designed and made by ourselves, were
applied to staple microwells on agarose gels. To achieve desired sizes of β-cells spheroids,
1 mL cell suspensions of different concentrations: 0.1x106, 0.8x106, 2.4x106, 5.6x106,
and 1.2x107 cells/mL, were seeded into microwells. Cells in the microwells were
incubated at 37 ºC and 5% CO2 2 days for β-cells spheroids formation. The formed βcells spheroids were transferred into a suspension flask on a shaker for long time culture.

4.2.4

Viability of cells in microwells
Viability of the cells in agarose microwells was examined using LIVE/DEAD

Viability Kit, which is a two color fluorescent assay based on differential permeability of
live and dead cells and allows preservation of the distinctive staining pattern for a couple
of hours after post-fixation with 4% (w/v) glutaraldehyde. Live cells were stained with
green fluorescent SYTO 10; and dead cells with compromised cell membranes were
stained with red fluorescent ethidium homodimer-2. A confocal laser microscope (TCS
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SP5, Leica microsystem Inc., Bannockburn, IL) was used to capture the images of the
LIVE/DEAD cell staining patterns.

4.2.5

Morphology of spheroids
Morphology of spheroids was examined by immunocytochemistry. The spheroids

were fixed with 4% (w/v) paraformaldehyde, treated with 5% goat serum in phosphate
buffered saline (PBS) to block non-specific reactivity and incubated overnight at 4 ºC
with primary antibodies, such as insulin and human mitochondria. After washing with
PBS three times, the samples were incubated with the affinity secondary antibodies at
room temperature for 3 hrs. The nuclei were stained with DAPI. The samples were
imaged using a Leica TCS SP5 laser scanning confocal microscope.

4.2.6

Co-culture RIN-m cells and hMSCs
Mixed cell suspension of 2x106 cells/mL with a ratio of RIN-m cells to hMSCs at

1:1 was seeded into microwells. Cultured 3 days, the formed spheroids were inspected by
immunocytochemistry as described above and imaged by Leica TCS SP5 laser scanning
confocal microscope.

4.2.7

Co-culture β-cells spheroids and hMSCs
RIN-m cells (1x106 cells/mL) in the microwells were incubated 2 days for

spheroids formation. Then hMSCs (1x106 cells/mL) were seeded and co-cultured with the
formed β-cells spheroids in the microwells for another 3 days. The morphology of co-
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culture spheres was inspected through immunostaining as described before and imaged
by Leica TCS SP5 laser scanning confocal microscope.

4.2.8

Core/shell structure RIN-m/hMSCs complex fabrication

4.2.8.1 Fabrication of hydrogel coated β-cells spheroids
The methylcellulose coated β-cells spheroids were prepared as following. Briefly,
hydrogel precursor solutions were prepared through mixing 1 mL 4% (w/w)
methylcellulose solution and 0.1 ng/mL streptavidin. Βeta-cells spheroids with hydrogel
precursor solutions were poured into 10 mL of mineral oil (Sigma Aldrich, St. Louis, MO)
with the magnetic stirring at 300 rpm at 37 ºC. After half an hour, the β-cells spheroids
were centrifuged at 300 rpm for 5 min, washed 3 times with culture media. The β-cells
spheroids were fixed with 4% (w/v) paraformaldehyde, stained with DPAI for nuclei and
Sulfo-Cy3 NHS ester (Lumiprobe Corp, Hallandale Beach, FL) for coated
methylcellulose, and inspected by Leica TCS SP5 laser scanning confocal microscope.

4.2.8.2 Human MSCs coating
Human MSCs were washed with Hank’s Balanced Salt Solution (HBSS) 3 times.
Human MSCs of different concentrations (0.4x106, 0.8x106, 1.6x106, 3.2x106, and
6.4x106

cells/mL)

were

incubated

in

biotinylated

poly(ethylene

glycol)-N-

hydroxysuccinimide (biotin-PEG-NHS) solution(1 mg/mL) for 30 min at 37 ºC on the
shaker. Human MSCs were washed 3 times with HBSS and transferred to Petrie dish
with the β-cells spheroids for 30 min coating at 37 ºC on a shaker. The formed spheroid
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complex were stained by immunocytochemistry and inspected by Leica TCS SP5 laser
scanning confocal microscope.

4.2.8.3 Agarose hydrogel coating
Agarose hydrogels were selected for coating on the surface of RIN-m/hMSCs
hybrid spheroids using the similar coating method as described before. Briefly, 1 mL 2%
agarose solution was mixed with 700 to 1000 RIN-m/hMSCs spheroids and 15 mL of
mineral oil (Sigma Aldrich, St. Louis, MO) was added at 40 ºC. The mixture was
suspended with the magnetic stirring at 200 rpm to form agarose droplets then immersed
in an ice bath for 5min. The microbeads contained RIN-m/hMSCs spheroids were
washed 3 times with HBSS and then cultured in medium under 5% CO2 at 37 ºC. The
thickness of coated hydrogel was controlled through adjusting the stirring rate of mineral
oil. Stirring rate was set up at 100, 200, and 500 rpm, respectively. The complexes were
fixed with 4% (w/v) paraformaldehyde and inspected by the phase-contrast microscope.

4.2.9

Insulin release from hMSCs coated β-cells spheroids
Beat-cells spheroids coated with different concentrations of hMSCs (0.4x106,

0.8x106, 1.6x106, 3.2x106, and 6.4x106 cells/mL) were inspected for insulin release based
on the glucose stimulus. Briefly, culture medium were removed from samples and
washed twice with KRB solution. Samples were first placed in a low glucose
concentration (1.1 mM) for 45min, followed by incubation in a high glucose
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concentration solution (16.7 mM) for 1 h. The high glucose solutions were collected for
insulin measurement by ELISA kit.

4.2.10 Bioactivation of hMSCs to pro-inflammatory cytokines
Human MSCs were enzymatically detached from culture plates, counted, and
added (0.4x106, 0.8x106, 1.6x106, 3.2x106, and 6.4x106 cells/mL) to a 24-well plate with
35 β-cells spheroids of 200 µm compared to β-cells spheroids cultured alone. After 24 hrs,
the insulin release based on the glucose stimulus from β-cells spheroids was inspected as
described above.
Then these co-culture cells were exposed to a cocktail of pro-inflammatory
cytokines including 100 ng/mL interferon-γ (IFN-γ), 10 ng/mL tumor necrosis factor-α
(TNF-α), 0.5 ng/mL interleukin 1β (IL-1β) for another 24 hrs. The insulin secretion based
on the glucose stimulus from β-cells spheroids was inspected again as described above.
The change of insulin release after exposing to the pro-inflammatory cytokines was
calculated based on these two inspections.

4.2.11 Analysis of β-cells apoptosis by TUNEL assay
Cytokine induced β-cells damage was assessed by the TUNEL, a marker for cell
apoptosis. After culture as 4.2.10 described above, the β-cells spheroids were fixed with
4% w/v paraformaldehyde. An APO-BrdU TUNEL Assay Kit (Invitrogen, Grand Island,
NY) was utilized, in which an AlexaFluor 488 labeled anti-BrdU antibody was used for
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detection of apoptotic cells. Propidium iodide staining was performed to detect all the
cells.

4.2.12 Statistical analysis
Data are shown as mean ± S.D. Statistical analyses were performed using one
way ANOVA (analysis of variance) followed by Tukey’s post tests and the paired t-test
where appropriate. A probability (P) value of <0.05 was considered statistically
significant.

4.3 Results
4.3.1

Fabrication of β-cells spheroids with uniform size
In this study, the agarose microwells were firstly fabricated by our designed

computer controlled spheroid maker (Figure 4.1). Different concentrations of β-cells were
seeded into these agarose microwells. Beta-cells survived and aggregated in these
microwells (Figure 4.2 A). Beta-cells exhibited high viability (>95%, Figure 4.2 B). The
cell seeding concentration controlled the size of β-cells spheroids. Higher concentrations
of β-cells resulted in the spheroids with larger diameter (Figure 4.2 A and C). These cell
aggregates were transferred to a suspension flask on a shaker for long-term culture. Large
amounts of uniformed β-cells spheroids with different sizes (100, 200, 300, 400, and 500
μm) have been successfully fabricated at 1 week with very high viability as shown in
Figure 4.3.
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Figure 4. 1 (A) The computer controlled spheroid maker. (B and C) The fabrication
process of microwells. (D) Agarose microwells.

Figure 4. 2 (A) Beta-cells formed aggregates of different diameters of 200, 300, and 400
µm in microwells. (B) LIVE/DEAD staining of β-cells aggregates in microwells. Live
cells stained with green and dead with red. (C) The relationship between cell seeding
concentrations and spheroid diameters.
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Figure 4. 3 Beta-cells formed spheroids with different diameters of (A) 100, (B) 200, (C)
300, (D) 400, and (E) 500 µm transferred into a suspension flask for culture 1 week with
high viability. Live cells stained with green and dead with red. Scale bar = 200 µm.
4.3.2

Glucose-stimulated insulin secretion
As shown on Figure 4.4, β-cells in the spheroids stained strongly positive for

insulin regardless of spheroid size, indicating that these cells were still capable of
producing insulin after in vitro culture in the format of spheroids.
For stimulated insulin secretion, β-cells spheroids were first conditioned in Krebs
Ringer Buffer (KRB) containing low glucose and then exposed to KRB containing high
glucose. Figure 4.5 reports insulin secretion from β-cells spheroids of different sizes at
high glucose level. The insulin released from the single cell was also calculated through
dividing the insulin amounts by the total cells in the spheroids. The spheroids of 200 µm
released significantly larger amount of insulin than those of 100 µm (* P<0.05). And
there is no significant difference about total insulin released from the spheroids of 200,
300, 400, and 500 µm. In consideration to the capacity of the single cell for insulin
secretion in the format of spheroids, the single cell from spheroids of 200 µm released
highest amount of insulin when compared to that from spheroid of 300 400, and 500 µm
(* P<0.05).
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Figure 4. 4 Insulin (green) staining of β-cells spheroids with different diameters of (A)
200, (B) 300, and (C) 500 µm. Nuclei were stained with DAPI (blue). Scale bar = 100
µm.
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Figure 4. 5 Insulin release from β-cells spheroids with different diameters of 100, 200,
300, 400, and 500 µm. (A) Insulin release from spheroids of total number of 270.
Spheroids of diameter of 200 µm released significant larger amount of insulin than those
with diameter of 100 µm (* P<0.05). (B) Insulin release from the single cell in the
spheroids. Cells from spheroids of 200 µm released lager amount of insulin compared to
those from spheroid of 300 µm (* P<0.05).
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4.3.3

Human MSCs invasion into β-cells spheroids
Human MSCs were stained with red by human specific antibody, mitochondria,

and RIN-m cells were identified with green by a polyclonal antibody directed against
murine insulin. When seeding these two types of cells in the microwells simultaneously,
as shown on Figure 4.6A, these cells self-assembled into a spheroid in which hMSCs
have integrated with each other and self-sorted to stay inside whereas β-cells randomly
disseminated throughout the entire spheroid. Moreover, a thin layer of β-cells appeared to
cover the whole spheroid.
When β-cells seeded first in the microwells, they aggregated together at the day 2.
The subsequently seeded hMSCs in the same microwells did not adhere on the surface of
the formed β-cells spheroids; instead, they invaded into β-cells spheroids and broke the
integrity of β-cells spheroids regardless of the diameter of spheroid, as shown in Figure
4.6B.
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Figure 4. 6 (A) Co-culture of β-cells and hMSCs. (B) Co-culture of β-cells spheroids
with hMSCs. Beta-cells were stained with insulin with green. Human MSCs were
identified by human mitochondria with red. Scale bar = 100 µm.

4.3.4

Construction of unique RIN-m/hMSCs complex with core/shell structure
To prevent the invasion of hMSCs, a physical barrier, methylcellulose hydrogel,

was coated on the surface of β-cells spheroids. Methylcellulose hydrogel formed a nano
layer on the spheroid (Figure 4.7).
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Figure 4. 7 Methylcellulose was coated on the surface of β-cell spheroid.
Methylcellulose was conjugated with Cy3 NHS ester (red) and DAPI for nuclei (blue).
Scale bar = 100 µm.
After nano-coating of hydrogel on the surface of β-cell spheroid, hMSCs attached
on the β-cell spheroid with shell-structure. The thickness of shell can be adjusted by the
concentration of hMSCs. As shown on Figure 4.8, with increasing the concentration of
hMSCs, a thicker shell layer formed on the surface of β-cell spheroid.
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Figure 4. 8 Human MSCs of different concentrations of (A) 0.4, (B) 0.8, (C) 1.6, and (D)
3.2 million/mL were coated on the surface of β-cell spheroid. Human MSCs were stained
with human mitochondria antibody with red, β-cell spheroid was identified by insulin
antibody (green) and DAPI for nuclei (blue). Scale bar = 100 µm.

4.3.5

Insulin secretion from RIN-m/hMSCs hybrid spheroids
To check the effects of coating of hMSCs on the insulin secretion from β-cell

spheroids, RIN-m/hMSCs hybrid spheroids were first conditioned in KRB containing low
glucose and then exposed to KRB containing high glucose. As shown in Figure 4.9, the
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amounts of secreted insulin decreased with increasing of hMSC concentration. When the
concentration caught up to 106 cells, the insulin secretion reduced significantly (*
P<0.05).
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Figure 4. 9 Insulin release from β-cells spheroids with diameter of 200 µm coated with
different concentrations of hMSCs. Spheroids of diameter of 200 µm coated with the
concentration of hMSCs of 0.8 million cells/mL released significant larger amount of
insulin than those with 1.6 million cells/mL (* P<0.05).
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4.3.6

Effects of hMSCs on β-cells spheroids
Before exposure of pro-inflammatory cytokines, co-culture with hMSCs for 24

hrs did not enhance glucose stimulated insulin secretion of β-cells regardless of hMSC
concentration (Fig. 4.10 A). Without hMSCs, exposure to cytokines significantly
debilitated the insulin secretion of β-cells (Fig. 4.10 B, 38%). Co-cultured hMSCs
benefited β-cells to retain the insulin secretion. The protective effect of hMSCs was dosedependent. High concentrations of hMSCs preserved β-cells to secrete insulin due to
glucose stimulation when exposed to pro-inflammatory cytokines. Specifically, with
hMSCs of 6.4 x 106/mL, β-cells only lost 8% of insulin secretion when compared after
and before exposure to pro-inflammatory cytokines
B
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Figure 4. 10 Beta-cells spheroids with the diameter of 200 µm co-cultured with different
concentrations of hMSCs. (A) Insulin release from β-cells spheroids co-culture with
hMSCs of different concentrations at 24 hr. (B) Percentage change of insulin release after
exposing to the pro-inflammatory cytokines after 24 hr (* P<0.05).

107

Figure 4.11 showed apoptosis of β-cells co-cultured with hMSCs of different
concentrations of 0, 0.4, 0.8, 1.6, 3.2, and 6.4 x 106/mL after exposing to the proinflammatory cytokines for 24 hrs. AlexaFluor 488 labeled anti-BrdU antibody was used
for detection of apoptotic cells. Propidium iodide was applied to stain all the cells. With
the increase of hMSC concentration, lower number of β-cells expressed apoptosis.
Human MSCs benefited β-cells survival when exposed to pro-inflammatory cytokines.

Figure 4. 11 Apoptosis of β-cells with the diameter of 200 µm co-cultured with hMSCs
of different concentrations: (A) 0, (B) 0.4, (C) 0.8, (D) 1.6, (E) 3.2, and (F) 6.4
million/mL after exposing to the pro-inflammatory cytokines. AlexaFluor 488 labeled
anti-BrdU antibody was used for detection of apoptotic cells and propidium iodide
staining for all the cells. Scale bar = 100 µm.
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4.3.7

Agarose hydrogel coating
Agarose hydrogel was coated on the surface of complex. Through controlling the

stirring rate, hydrogel out layer formed on the surface of RIN-m/hMSCs hybrid spheroids
with different thicknesses of 5, 20, and 60 μm, as shown in the Figure 4.12.

Figure 4. 12 Agarose was coated on the surface of complex. Through controlling the
stirring rate, hydrogel outlayer of different thicknesses of (A) 5, (B) 20, and (C) 60 µm
can be formed on the surface of β-cell spheroid-hMSCs complex. Scale bar = 100 µm.

4.4 Discussion
Isolated cells from pancreatic islets and immortalized β-cells lines require contact
with other cells or basement membrane proteins, or mimicry of these contacts to maintain
function and viability when cultured in synthetic in vitro systems. Recognizing this
requirement, different approaches have been developed that encourage or increase cellcell contact for β-cells such as cell encapsulation, cellular co-culture with MSCs, cell
aggregates, and so on. For cell aggregates, typical methods are hanging drop culture,
round-bottomed 96-well culture, non-adhesive plate culture, agitation culture, and so on.
Non-adhesive plate and agitation culture are difficult to control sphere diameter whereas
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hanging drop culture is hard to handle spheres. Recently, a novel technique, highthroughput hydrogel microwells, has been developed to achieve mass sphere production
with easy spheroid handling and diameter control. In this study, we have designed a
computer controlled spheroid maker, which can produce mass spheroids automatically.
Uniformed β-cell spheroids, derived from RIN-m cells, have been successfully fabricated.
The size of β-cell spheroids can be manipulated through adjusting the cell seeding
concentrations and recess diameters of micro-molds. These spheroids were readily
removed from the devices and maintained their size and shape, presumably due to strong
cell-cell attachment and low cell-material adhesion.
The first relates to cell aggregates is central necrosis. Although often seen during
the culture of intact islets, the re-aggregated β-cells did not show signs of central necrosis,
as the cell-permeable viability dye were able to penetrate to the interior of the aggregates
and the central cells also stained green (Figure 4.3).
The maintenance of functional expression throughout cell manipulation is
important for β-cells. The cells preserved intracellular insulin content at high levels as
evidenced by immunostaining. The model β-cells used in this work did not show a sizedependent effect on cellular viability, but on functional expression. The bigger spheroids
released more insulin. However, the same number of cells released more insulin from
smaller spheroids in the range of 100-200 µm (Figure 4.5). It may imply that the spheroid
of 300 µm is too big, cells in the core of spheroids have limited response to glucose; and
then the function of the cells in the core may be compromised.

110

Mesenchymal stem cells, multipotent stromal cells with the potential to give rise
to cells of diverse lineages, have been noted to possess the ability to impart profound
immunomodulatory effects in vivo. MSCs were found to down-regulate T and B
lymphocytes, natural killer cells and antigen presenting cells through various
mechanisms, including cell to cell interaction and soluble factor production [30].
Aggregation of MSCs into three dimensional spheroids has shown to be more effective
than MSCs from adherent monolayer cultures in suppressing inflammatory responses in a
co-culture system with lipopolysaccharide-activated macrophages and in a mouse model
for peritonitis [30]. Furthermore, MSCs can secret trophic molecules to enhance survival,
function, and angiogenesis of isolated islets after co-transplantation of islet and MSCs
[5].
To construct core/shell structured complex of RIN-m/hMSCs, first of all, we have
seeded these two types of cells in microwells simultaneously, the cells self-assembled
into a spheroid and self-sorted with hMSCs integrating with each other and staying inside
encapsulated by a thin layer of RIN-m cells. Human MSCs and RIN-m cells have
different cohesive forces (like-to-like) and adhesive forces (unlike binding). Self-sorting
occurs due to these differences with hMSCs of higher cohesion in the core and RIN-m
cells with lower cohesion on the outside. Moreover, the differences in cytoskeletal
mediated tension between these two types of cells may also result in self-sorting.
When co-culturing hMSCs with β-cells spheroids, hMSCs invaded into spheroids.
To successfully construct core/shell structured β-cells spheroids/hMSCs complex, we
have to inhibit hMSCs invasion. In this study, a physical barrier, non-degradable
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hydrogel, was applied between β-cell spheroids and hMSCs. This hydrogel effectively
inhibited hMSCs invasion. The hydrogel also served as another temperately shell for βcells spheroids away from the hostile destruction as immunoisolation, which may further
improve the survival of β-cells aggregates in vivo.
The maintenance of functional expression throughout cell manipulation is
important for β-cell spheroids after coating. RIN-m spheroids were shown to maintain
their functional expression throughout seeding, aggregation, culture, and coating. The
coating cell concentration influenced the insulin secretion from β-cells spheroids. While
compared to the co-culture data of hMSCs and β-cell spheroids, hMSCs did not enhance
the insulin secretion in co-culture samples, which means the coating thickness is
important to maintain the function of β-cells spheroids. To measure the beneficial effects
of this co-culture strategy, we investigated the function of β-cell spheroids exposed to
pro-inflammatory cytokines. We found that co-culture hMSCs with β-cell spheroids can
protect β-cell spheroids from pro-inflammatory cytokines.

4.5 Conclusion
In this study, different sizes of uniformed β-cells spheroids were successfully
fabricated through our automatic high-throughput spheroid maker. Single β-cell in the
spheroid with the diameter of 200 µm expressed strongest insulin secretion compared to
other sizes of 100, 300, 400 and 500 µm. The novel core-shell structured spheroidshMSCs complex was achieved through coating hydrogels as physical barrier on the
surface of β-cells spheroids to inhibit hMSCs invasion. The thickness of hMSCs coating
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affected the insulin secretion. Human MSCs prevented β-cells spheroids apoptosis and
benefited insulin secretion when exposed to pro-inflammatory cytokines. This study
provides a new therapeutic approach to treat type 1 diabetes in which cell therapies may
be essential.
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CHAPTER FIVE
5

LIF, IL-10 AND VEGF-LOADED NANOPARTICLES COATED MSC
MICROENCAPSULATED BETA-CELL SPHEROIDS

5.1 Introdution
Type 1 diabetes, referred to as insulin-dependent diabetes mellitus, is an
autoimmune disease resulting from the destruction of β-cells located in the islets of
Langerhams of pancreas by autoantigen-reactive T lymphocytes (T cells) which produce
immune factors to attack and destroy β-cells of pancreas [1]. T cells specific for
pancreatic islet β-cell constituents (auto-antigens) exist normally but are restrained by
regulatory mechanisms (self-tolerant state). When regulation fails, β-cell specific
autoreactive T cells become activated and expand clonally. The pathogenic immune
response would lead to islet inflammation. This is characterized by infiltration of the islet
by macrophages and T cells that are cytotoxic, both directly and indirectly by producing
cytokines [e.g., interleukin 1 (IL-1), tumor necrosis factor α (TNFα), TNFβ, and
interferon γ (IFNγ)] and free radicals that damage β-cells. Current evidence indicates that
islet β-cell specific autoreactive T cells belong to a T helper 1 (Th1) subset, and these
Th1 cells and their characteristic cytokine products, IFNγ and IL-2, are believed to cause
islet inflammation and β-cell destruction [2, 3]. Several approached are being tested or
are under consideration for clinical trials to prevent or arrest complete autoimmune
destruction of islet β-cells and insulin-dependent diabetes. Approaches for the treatment
of type 1 diabetes aimed at deleting β-cell autoreactive Th1 cells and cytokines (IL-1,

TNFα, TNFβ, and IFNγ) and increasing regulatory Th2 cells and/or Th3 cells and their
cytokine products (IL-4, IL-10 and TGFβ1).
Th1 cells and Th2 cells secrete cytokines to lead to strikingly different T cell
actions. Th1 cells produce IL-2, IFNγ, and TNFβ which attack islet β-cells, while Th2
secrete IL-4 and IL-10 to inhibit the production of the Th1 cytokines. IL-10 may favor
Th2 over Th1 cell differentiation and function by inhibiting expression of MHC class II
molecules and the B7 accessory molecule on macrophages, a major co-stimulator of T
cells. IL-10 is effective in inhibiting Th1 effector function. The cytokine milieu
specifically is critical for orchestration of lineage development towards aggressive
effector T cell (Teff) or tolerant Treg phenotypes. Leukemia inhibitory factor (LIF)
belongs to the IL-6 family of structurally related cytokines. LIF is associated with Tregs
and immune tolerance [4]. LIF can reduce the inflammatory immune response in vivo by
promoting regulatory Treg [5]. In addition to promoting immune tolerance via Treg, LIF
is also well known to promote islet cell survival and LIF regulates β-cell mass [6, 7].
Pancreatic islets are well vascularized throughout life. This is important for their
ability to secrete insulin swiftly in response to changes in blood glucose. Reestablishment
of blood flow to transplanted islets requires several days. Rapid and adequate
revascularization of transplanted islets is critical for islet survival and function. Delayed
and insufficient revascularization can result in islet cell death and early graft failure.
Therefore, developing strategies aimed at enhancing or accelerating this process is
extremely important [8].
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Figure 5. 1 (A) The scheme of our core-shell structured β-cells/hMSCs/hydrogels
complex. (B and C) The β-cells spheroids/hMSCs complex coated with agarose hydrogel
mixed with LIF, VEGF and IL-10 loaded nanoparticles. Scale bar = 100 µm.
To further improve the viability and suppress the immune rejection, a drug
delivery system is really needed to delivery angiogenic and immune regulatory molecules
like vascular endothelial growth factor (VEGF), IL-10 and LIF. Among drug delivery
systems, poly (lactide-co-glycolide) (PLGA) nanoparticles have already demonstrated
their potential for growth factors or immune regulatory molecules delivery in tissue
equivalents. As temporally controlled systems, PLGA nanoparticles can protect the
protein and release it at a specific time and for long time frames during tissue
development [9-11]. In this study, we loaded IL-10, LIF, and VEGF into degradable
PLGA nanoparticles and loaded nanoparticles into outside layer of agarose hydrogel, as
Figure 5.1 shown, for sustained release; we then inspected the biological activities of
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released IL-10 and LIF on survival and function of β-cells spheroids against proinflammatory cytokines, and the bioactivity of VEGF released from nanoparticles on the
culture of human aortic endothelial cells.

5.2 Materials and methods
5.2.1

Materials
PLGA (50:50) was purchased from Sigma Chemical Co. (St. Louis, MO). Human

interleukin 10 (IL-10) and rat VEGF were purchased from PeproTech (Rock Hill, NJ).
Human LIF was purchased from Millipore (Billerica, MA). LIF enzyme-linked
immunosorbent assay (ELISA) kit was obtained from Raybiotech, Inc. (Norcross, GA).
IL-10 and VEGF ELISA kits were obtained from Sigma Aldrich. (St. Louis, MO).
Transwell inserts of 8 μm pores were purchased from Greiner Bio-One (Monroe, NC).
All other reagents were purchased from Sigma Aldrich (St. Louis, MO).

5.2.2

Cell culture
Rat pancreatic β-cells of the RIN-m cell line were obtained from ATCC (CRL-

2057). RIN-m cells were cultured in Roswell Park Memorial Institute (RPMI) 1640
medium supplemented with 10% fetal bovine serum at 37 ºC in humid conditions with
5% CO2. The culture medium was exchanged every 2 days.
Human aortic endothelial cells (HAECs) were obtained from Sciencell (Carlsbad,
CA). HAECs were maintained in endothelial cell medium supplemented with 5% fetal
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bovine serum and 1% AA (Penicillin-Streptomycin). HAECs were incubated at 37 °C
under 5% CO2. Medium was changed every 3 days.

5.2.3

Fabrication of IL-10, LIF and VEGF-loaded PLGA nanoparticles
The IL-10, LIF, and VEGF-loaded PLGA nanoparticles were prepared using a

water-in oil-in-water (W1/O/W2) solvent extraction/evaporation technique. Briefly, using
LIF as an example, 2 μg LIF previously dissolved in a 1 mL 1% bovine serum albumin
(BSA) buffer was emulsified by ultrasound (Branson Sonifier, CT) in 2 mL methylene
chloride containing 50 mg PLGA for 5 min. This emulsion was poured into 10 mL of 1%
polyvinyl acetate and emulsified by magnetic stirring at 500 rpm. After evaporation of
the methylene chloride at room temperature for 4 hr, the nanoparticles were centrifuged
at 14,000 rpm for 30 min, washed five times with deionized distilled water, and then
lyophilized. The size and morphology of PLGA nanoparticle were inspected with
Nanosizer/Particle Size Analyzer (Delsa™, Beckman Coulter, Inc.) and scanning electron
microscope (SEM, JSM-5610, JEOL, Japan), respectively.

5.2.4

IL-10, LIF and VEGF release from PLGA nanoparticles
The release kinetics of IL-10, LIF, and VEGF from PLGA nanoparticles were

examined in a phosphate buffered saline (PBS) buffer supplemented with 1% BSA and
10 μg/mL of heparin at 37 °C, respectively. First, 3.5 mg of molecules-loaded PLGA
nanoparticles was placed with 1% agarose hydrogel and then added 1 mL of buffer
solutions in 15 mL tubes. The 1 mL of buffer was removed and the buffer was replaced
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each time to maintain constant volume. The amount of molecules actually loaded within
the PLGA nanoparticles was measured via extraction with 0.05N NaOH. Freeze-dried
loaded nanoparticles (2mg, n-3) were dissolved with 1 mL of 0.05N NaOH under stirring.
After 24 h, the solutions were centrifuged at 5000 rpm and the supernatant analyzed for
growth factor content by ELISA. The amount of molecules released from nanoparticles
was measured using ELISA kits. Cumulative release kinetics was calculated by
normalizing the total release at each time point with the total loaded amount in
nanoparticles.
5.2.5

Bioactivity of LIF and IL-10 nanoparticles to pro-inflammatory cytokines
Thirty five β-cell spheroids per well were seeded to a 24 wells plate, a transwell

insert was added into the well with LIF and IL-10 nanoparticles. Then these co-culture
samples were exposed to a cocktail of pro-inflammatory cytokines including 100 ng/mL
interferon-γ (IFN-γ), 10 ng/mL tumor necrosis factor-α (TNF-α), 0.5 ng/mL interleukin
1β (IL-1β) for 24 hrs. Culture medium were removed from encapsulation samples for
glucose-stimulated insulin secretion and washed twice with KRB solution. Samples were
first placed in a low glucose concentration (1.1 mM) for 45min, followed by incubation
in a high glucose concentration solution (16.7 mM) for 1 hr. The high glucose solutions
were collected for insulin measurement by ELISA insulin kit.

5.2.6

Analysis of β-cells apoptosis by TUNEL assay
Cytokine induced β-cells damage was assessed by the TUNEL, a marker for cell

apoptosis. After culture as 5.2.5 described above, the β-cells spheroids were fixed with
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4% w/v paraformaldehyde. An APO-BrdU TUNEL Assay Kit (Invitrogen) was utilized,
in which an AlexaFluor 488 labeled anti-BrdU antibody was used for detection of
apoptotic cells. Propidium iodide staining was performed following to detect all the cells.

5.2.7

Bioactivity of VEGF released from nanoparticles
The bioactivity of released VEGF from the PLGA nanoparticles was evaluated in

vitro by determining the proliferative capacity of the HAECs. The CyQUANT cell
proliferation assay kit was used to assess proliferation of the HAECs treated with
nanoparticles supernatant and exogenous VEGF. The HAECs were plated in a density of
4000 cells/well in a 96-well plate. After 24 hours, the endothelial cell medium was
removed and treated with exogenous VEGF (final concentration: 8, 16, and 32 ng/mL),
and supernatant from VEGF nanoparticles (final concentration: 8, 16 and 32 ng/mL).
After the 72 hrs, the contents of the assay wells were removed. Subsequent cell labeling
with the CyQUANT reagent was according to the manufacturer’s instructions.
Microplates were read by plate reader.

5.2.8

Loaded nanoparticles in RIN-m/hMSCs hybrid spheroids
The agarose hydrogel was mixed with biodegradable polyethylene glycol (PEG)

hydrogel as the ratio of 1:1 to prepare hydrogel solution, and then the nanopaticles were
mixed with hydrogel solution for RIN-m/hMSCs hybrid spheroids coating. The applied
coating method was the same as chapter 4.2.8 described
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5.2.9

Statistical analysis
Data are shown as mean ± S.D. Statistical analyses were performed using oneway

ANOVA (analysis of variance) followed by Tukey’s post tests and the paired t-test where
appropriate. A probability (P) value of <0.05 was considered statistically significant.

5.3 Results and discussion
5.3.1

LIF and IL-10 nanoparticles
Figure 5.2 shows the morphology of LIF-loaded PLGA particles with a uniform

size of approximately 400 nm (Figure 5.2 B). As Figure 5.3 shows, LIF can be released
from PLGA nanoparticles in a controlled manner over 1 month. During the first 3 days,
approximately 50% of total loaded LIF was released from the nanoparticles, followed by
a steady release over 3 weeks. Another burst release occurred at 4 weeks due to the
degradation and collapse of PLGA nanoparticles. During the first 3 days, LIF released
from 3.5 mg nanoparticles was maintained at about 15 ng per day (Figure 5.3 B). Figure
5.4 reports the release profile of IL-10 from PLGA nanoparticles. IL-10 released from
PLGA nanoparticles in a controlled manner about 6 weeks with a burst release of 27%
during the first 3 days. These release profiles are similar to previous reports by other
researchers [9, 11-13].
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Figure 5. 2 (A) LIF-loaded PLGA nanoparticles. (B) The average particle size is 400 nm.

Figure 5. 3 Cumulative in vitro LIF (A) percentage release from PLGA nanoparticles and
(B) release amounts from 3.5 mg nanoparticles during the first 7 days.
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Figure 5. 4 Cumulative in vitro IL-10 cumulative percentage release from PLGA
nanoparticles.
5.3.2

Bioactivity of released IL-10 and LIF to pro-inflammatory cytokines
To investigate the effects of IL-10 and LIF on protecting β-cells spheroids from

pro-inflammatory cytokines, such as interferon-γ, tumor necrosis factor-α, and interferon
1β, glucose stimulated insulin secretion was used to assess β-cell function in a two hour
static incubation assay at low and high glucose concentrations. As shown in Figure 5.5,
cytokine exposure significantly altered glucose stimulated insulin secretion of β-cells.
Without nanoparticles, exposure to cytokines decreased insulin secretion of β-cells (38%
lost when compared after and before exposure). In contrast, with nanoparticles, β-cells
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lost 33% of insulin secretion. IL-10 and LIF loaded nanoparticles did not significantly
preserve glucose stimulated insulin secretion. Apoptosis of β-cells cultured under these
cytokines with LIF and IL-10 loaded nanoparticles or blank nanoparticles was shown in
Figure 5.6. IL-10 and LIF did not prevent the apoptosis of β-cells. The reason lies in the
facts that IL-10 is effective in inhibiting Th1 effector function whereas LIF is associated
with Tregs [7, 14]. Especially, IL-l0 (derived from macrophages and Th2 cells) exerts
anti-inflammatory effects by inhibiting production of IL-12 and other pro-inflammatory
macrophage cytokines (e.g., IL-1, IL-6, IL-8, TNFα), by increasing macrophage
production of IL-1 receptor antagonist, and by inhibiting the generation of oxygen and
nitrogen free radicals by macrophages. Both IL-10 and LIF do not directly affect the βcells. Since the situation in vitro (no T cells involving) is totally different from that in
vivo, the further in vivo study will prove the benefits of LIF and IL-10 on survival and
function β-cells [15, 16].
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Figure 5. 5 Beta-cells spheroids with the diameter of 200 µm cultured with LIF and IL10 loaded nanoparticles with a cocktail of cytokines of interferon-γ, tumor necrosis
factor-α, and interferon 1β.

5.3.3

Bioactivity of released VEGF on HAECs
Figure 5.7 reports the release profiles of VEGF from PLGA nanoparticles. VEGF

can be released from PLGA nanoparticles about 6 weeks in a controlled manner. The
bioactivity of the VEGF released from the nanoparticles over time was assessed using an
in vitro HAEC proliferation assay shown in Figure 5.8. Endothelial cells response to
bioactive VEGF by proliferating is dose-dependent. These cells exposed to exogenous
VEGF at the concentration of 16 ng/mL exhibited the highest proliferation rate when
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compared to 8 and 32 ng/mL (* P<0.05). In addition, the VEGF released from
nanoparticles was as potent as exogenously added VEGF to enhance the proliferation of
HAECs.

Figure 5. 6 Apoptosis of β-cells with the diameter of 200 µm cultured (A) with LIF and
IL-10 loaded nanoparticles and (B) blank nanoparticles with a cocktail of cytokines of
interferon-γ, tumor necrosis factor-α, and interferon 1β. AlexaFluor 488 labeled antiBrdU antibody was used for detection of apoptotic cells and propidium iodide staining
for all the cells. Scale bar = 100 µm.

128

Percentage of Cumulative Release (%)

120
100
80
60
40
20
0
0

10

20

30

40

50

Time (days)

Figure 5. 7 Cumulative in vitro VEGF cumulative percentage release from PLGA
nanoparticles.

Figure 5. 8 The bioactivity of the VEGF assessed using an in vitro HAEC proliferation
assay. (A) The proliferation of HAEC affected by the concentration of VEGF. (B)
Comparison of VEGF solution and VEGF released from nanoparticles on the
proliferation of HAEC (* P<0.05).
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5.3.4

Loaded nanoparticles in RIN-m/hMSCs hybrid spheroids
In this study, we design a hydrogel system mixed with non-degradable hydrogel

(agarose) and biodegradable hydrogel (PEG). Growth factors loaded nanoparticels have
been mixed with the hydrogels before the coating process. Hydrogel out layer formed on
the surface of RIN-m/hMSCs hybrid spheroids with the thickness of 20 μm was shown in
the Figure 5.9.

Figure 5. 9 The β-cells spheroids/hMSCs complex coated with agarose hydrogel mixed
with LIF, VEGF and IL-10 loaded nanoparticles. Scale bar = 100 µm.

5.4 Conclusion
In this chapter, LIF, IL-10 and VEGF loaded PLGA nanoparticles have been
successfully fabricated through solvent extraction/evaporation techniques. These growth
factors can be controlled release about 6 weeks. The bioactivity of released VEGF has
been confirmed by the in vitro HAEC proliferation assay. The LIF and IL-10 did not
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preserve the capacity of glucose stimulated insulin secretion of β-cells in vitro when
exposure to the pro-inflammatory cytokines.
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CHAPTER SIX
6

IN VIVO EVALUATION OF BETA-CELLS/MSC HYBRID SPHERIODS FOR
THE TREATMENT OF TYPE 1 DIABETES

6.1 Introduction
Islet transplantation, which can restore the recipients’ ability to secrete insulin in a
physiological manner, is the most promising approach to treat patients with type 1
diabetes. However, there are two major problems hindering this process. First, not
enough donor islets are available for transplantation. Second, the function of transplanted
islets is often compromised by the immune rejection response mounted to the grafts by
the recipients [1-4]. Immunosuppressive agents used so far have severe toxic side effects
and are sometime diabetogenic. Islet encapsulation with biocompatible materials can
exert both immunoisolation and immunomodulation effects by (1) physically isolating
islets from cytokines and host immune cells, and (2) delivering immune regulatory and
immunomodulatory factors/cells locally to the islets to protect those islets from immune
rejection [5-7]. Thus, with glycemia control well achieved by fewer donor islets,
encapsulation technology not only solves the problems of limited islet supply, but also
reduces/avoids the use of toxic immunosuppressants in the recipients.
The objective of this project is to develop an effective strategy for the treatment of
type 1 diabetes using β-cells based replacement therapy. To improve the viability of
transplanted β-cells, one novel approach is to transplant an optimal size range of β-cell
spheroids rather than a cell suspension. Uniform sized multi-cellular spheroids can be
coated with a thin layer of non-degradable hydrogel for immunoisolation. In addition, the

survival of spheroids of optimized size can be further improved with a novel coating of
multiple layers of mesenchymal stem cells (MSCs), a cell type that has profound
immunoregulatory effect, to prevent graft rejection [8]. To prevent MSCs from migrating
away from spheroids, another layer of non-degradable hydrogel can be added. To further
improve the viability and suppress the immune rejection, spheroids will be encapsulated
with nanoparticles loaded with angiogenic (vascular endothelial growth factor, VEGF) [9]
and immune regulatory molecules [interleukin-10 (IL-10) and leukemia inhibitory factor
(LIF)] [10, 11]. By this means, the spheroid will passively evade the complications of
stressors in addition to actively modulating the immune microenvironment for regulatory
tolerance and long-term engraftment.

6.2 Materials and Methods
6.2.1

Materials
F40/80 and CD-31antibodies were purchased from Abcam (Cambridge, MA).

FOXP3 antibody was obtained from LifeSpan Bioscience (Seattle, WA); Insulin antibody
was obtained from Santa Cruz Biotechnology (Dallas, Texas); Human mitochondria
antibody was purchased from Millipore (Billerica, MA). Fluorophore-conjugated
secondary antibodies were purchased from Jackson ImmunoResearch (West Grove, PA).
All other reagents were purchased from Sigma Aldrich (St. Louis, MO).

6.2.2

Animals
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Male C57BL/6 mice at 6–8 weeks of age were purchased from the Jackson
Laboratory (Bar harbor, ME). All procedures were carried out using animals less than 12
weeks old and protocols were approved by the IACUC committee at Medical University
of South Carolina.

6.2.3

Animal model and spheroids transplantation
C57BL/6 (H-2b) mice were rendered diabetic by one-time injection of

streptozotocin (STZ) given intraperitoneally at 225 mg/kg as described before [12]. Five
days after STZ administration, mice with two consecutive blood glucose levels exceeding
350 mg/dL were deemed diabetic and used as recipients. Beta-cell spheroids were
transplanted under the kidney capsule of each recipient. There were 4 groups (n=5/group).
Group I: β-cells spheroids; Group II: β-cells spheroids/hMSCs; Group III: β-cells
spheroids/hMSCs coated with agarose hydrogel; Group IV: β-cells spheroid/hMSCs
coated with porous hydrogel mixed with IL-10, LIF and VEGF loaded-nanoparticles.
Beta cell function was monitored indirectly by measuring blood glucose levels twice per
week.

6.2.4

Tissue processing, histology and immunohistochemistry
Beta-cells spheroid grafts including a portion of the kidney were harvested at the

day 3, 9 and 30 post-transplantation. They were immediately rinsed in phosphate buffered
saline (PBS), embedded in optimal cutting temperature compound, frozen, and sectioned
on a cryostat according to routine histologic procedures. The sections (5 μm thick) were
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fixed with 4% (w/v) paraformaldehyde. For immunostaining, sections were
permeabilized with 0.5% Triton X-100 and blocked with 4% normal goat serum in PBS
for 2 hr. Primary antibodies were then applied overnight at 4 °C. The following primary
antibodies were used: F40/80 to detect the expression of infiltrated macrophages inside
the graft, CD-31 to identify the endothelial cells for angiogenesis, FOXP3 to inspect the
regulatory T cells, and human mitochondria to check the survived human MSCs. Cy3
affinity secondary antibodies and goat anti-mouse and rabbit were used at 1:400. The
specimens were imaged using a LSM 510 Meta Confocal Microscope (Zeiss, Thornwood,
NY). At least 6 random fields per samples were analyzed for each group.

6.3 Results and discussion
6.3.1

Macro-inspection of transplantation of spheroids

Figure 6. 1 Macro inspection of spheroids transplantation. (A) The kidney has been
exposed for β-cells spheroids transplantation. (B) Beta-cells spheroids have been
transplanted under the kidney capsule. (C) Inspection of the β-cells spheroids after 3 days
post-transplantation .
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We have picked up the mouse as the species to construct the diabetes model since
fewer cells are needed for the treatment when compred to a rat used as the model. As
Figure 6.1 showed, the kidney has been exposed for spheroid transplantation. Beta-cell
spheroids have been successfully transplanted under the kidney capsule. Three days later,
these transplanted spheroids maintained their integrity and can be still identified.

6.3.2

Glucose level investigation
The function of transplanted β-cells was monitored indirectly by measuring blood

glucose levels. As shown in Figure 6.2, during the first 2 days in the group of spheroids
only, the glucose level was kept constant to that before transplantation (1.05 compared to
1). As for other three groups, all the glucose levels decreased a little bit. Without any
treatment, the glucose level will increase significantly to 500 mg/dL at the day 3. All
these results have implied that the transplanted β-cells worked with limited success to
prevent the increasing of glucose level.
1.4

Before

1d

2d

1.2

Relative Change of Glucose Level

1

0.8

0.6

0.4

0.2

0
Spheroids

Spheroids/hMSCs

Spheroids/hMSCs/Nano Spheroids/hMSCs/Gel

Figure 6. 2 Glucose level after transplanted different groups of β-cells spheroids at the
day 1 and 2.
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Long-term investigation of glucose level has been recorded in the Figure 6.3. The
glucose level of 500 mg/dL is assumed as failure control of the glucose condition. Based
on this assumption, the control group, without any transplanted cells, the glucose level
reached 500 mg/dL at the day 3 and increased with the time. During the inspection period
(30 days), these four treatment groups expressed different glucose modulation times: 7
days

for

spheroids,

14

days

for

spheroids/hMSCs/nano,

30

days

for

spheroids/hMSCs/gel, respectively. The 7-day of glucose control time for spheroids only
may imply that the survival of spheroids in vivo has significantly declined 7 days later
after transplantation. Spheroids co-transplanted with hMSCs have maintained the glucose
level during the whole period. Compared to spheroids only group, hMSCs may modulate
the host immune response and enhance survival of spheroids at the transplantation site.
The other two groups, both with a hydrogel out-layer, have exhibited limited success. The
hydrogel out-layer has a thickness of about 20 µm. This layer may have blocked the
response of β-cells to host glucose or inhibited the secreted insulin free diffusion from the
graft to host tissue. All these groups can not restore normoglycaemia and reduce the
glucose to normal level (<200 mg/dL) [13]. This may be due to the low number of
spheroids transplanted at first (just about 300) compared to the large number (>1000) of
islet transplantation in other studies [14, 15].
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Figure 6. 3 Glucose level after transplanted different groups of β-cells spheroids.

6.3.3

Survived hMSCs at the transplantation site
Human mitochondria have been used to identify the transplanted hMSCs shown

in Figure 6.4. Especially for the group of spheroids/hMSCs, a large number of hMSCs
survived at the transplantation site at day 30. In consideration to the spheroids with
hydrogels, at the day 9, hMSCs still maintained the shell structure even though the
encapsulated core, β-cells spheroids, had been lost during the histology process (Figure
6.4 G and H).
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Figure 6. 4 Human MSCs at the transplantation sites at the day of 3 (A-D), 9 (E-H) and
30 (I-L). (A, E and I) Beta-cells spheroids. (B, F and J) Beta-cells spheroids/hMSCs. (C,
G and K) Beta-cells spheroids/hMSCs coated with agarose hydrogel. (D, H and L) Betacells spheroid/hMSCs coated with porous hydrogel mixed with IL-10, LIF and VEGF
loaded-nanoparticles. Human MSCs were identified by mitochondria and nuclei by
DAPI. Scale bar: 100 µm.
6.3.4

Macrophages
Figure 6.5 showed macrophages at the transplantation sites. Only in the group of

spheroids, huge amounts of macrophages have existed all the time. As for the spheroids
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transplanted with hMSCs, although at day 3 large numbers of macrophages appeared, at
the day 9 the number of macrophages significantly decreased compared to spheroids
only, and at the day 30, just few macrophages appeared at the transplantation site. All
these results mean the hMSCs may suppress the inflammation at the transplantation site.
Interestingly, when the spheroids were coated with an out-layer of agarose hydrogel, the
spheroids did not induce an intense inflammation reaction especially at day 3. The IL-10,
LIF and VEGF loaded-nanoparticles further inhibited the inflammation response at the
day 3 (Figure 6.5 D compared to C). Moreover, very few macrophages existed all the
time with these two groups of spheroids/hMSCs/gel and β-cells spheroid/hMSCs/nano.
These spheroids with an out-layer of hydrogel were lost during the process of
immunhistochemsitry, which has been confirmed again by the empty pores on these
specimens (Figure 6.5 G, H and L).
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Figure 6. 5 Macrophages at the transplantation sites at the day 3 (A-D), 9 (E-H) and 30
(I-L). (A, E and I) Beta-cells spheroids. (B, F and J) Beta-cells spheroids/ hMSCs. (C, G
and K) Beta-cells spheroids/hMSCs coated with agarose hydrogel. (D, H and L) Betacells spheroids/hMSCs coated porous hydrogel mixed with IL-10, LIF and VEGF loadednanoparticles. Macrophages were identified by F40/80 and nuclei by DAPI. Scale bar:
100 µm.

6.3.5

Regulatory T cells
The regulatory T cells are supposed to be activated by transplanted hMSCs to

protect spheroids. As Figure 6.6 shows, no Foxp3+ cells were observed in tissue sections
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from all groups at 3 day following transplantation (Fig. A, B, C and D). At a later time,
many more Foxp3+ cells were observed surrounding cell grafts from hMSCs group and
nanoparticles loaded group, indicating that hMSCs initiated the regulatory T cells at day
9 and emphasized this activation further at day 30, and the IL-10, LIF and VEGF loadednanoparticles also activated regulator T cells at both day 9 and 30.

Figure 6. 6 Regulatory T cells at the transplantation sites at the day 3 (A, B, C and D), 9
(E, F, G, and H) and 30 (I, J, K and L). (A, E and I) Beta-cells spheroids. (B, F and J)
Beta-cells spheroids/hMSCs. (C, G and K) Beta-cells spheroids/hMSCs coated with
agarose hydrogel. (D, H and L) Beta-cells spheroids/hMSCs coated with porous hydrogel
mixed with IL-10, LIF and VEGF loaded-nanoparticles. T cells were identified by
FOXP3 and nuclei by DAPI. Scale bar: 100 µm.
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6.3.6

Blood vessels
Shown in the Figure 6.7, at day 3, there was no blood vessel formation at the

transplantation sites in all groups. Compared to spheroids only, when spheroids
transplanted with hMSCs, a blood vessel network had appeared at the transplantation site
(Figure 6.7 F). The network became much more intense and structured at the day 30
(Figure 6.7 J). This phenomenon is consistent with other studies in which hMSCs
benefited angiogenesis in vivo [16-18]. When considereing the VEGF loaded
nanoparticles in comparison to the gel group (Figure 6.7 G to H and K to L), the release
of VEGF significantly enhanced the vasculature formation at the transplantation site.
Well-structured blood vessel networks formed in the group of spheroids/hMSCs/nano,
especially at day 30, and were consistent with other studies [19-21].
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Figure 6. 7 Blood vessels inspected at the transplantation sites at the day 3 (A-D), 9 (EH) and 30 (I-L). (A, E and I) Beta-cells spheroids. (B, F and J) Beta-cells
spheroids/hMSCs. (C, G and K) Beta-cells spheroids/hMSCs coated with agarose
hydrogel. (D, H and L) Beta-cells spheroid/hMSCs coated with porous hydrogel mixed
with IL-10, LIF and VEGF loaded-nanoparticles. Blood vessels were identified by CD-31
and nuclei by DAPI. Scale bar: 100 µm.

6.4 Conclusion
In this study, β-cell spheroids were transplanted under the kidney capsule to treat
diabetic mice. Beta-cells spheroids can keep the glucose level of diabetic mice constant.

145

Co-transplanted hMSCs can suppress the host inflammation response, activate the
regulatory T cells and also promote angiogenesis at the transplantation sites. The β-cells
spheroids/hMSCs/hydrogel complex initiated a mild inflammatory response. The LIF and
IL-10, and VEGF loaded complex can further inhibit this response and promoted blood
vessel network formation at the transplantation site. Our approach holds a great potential
to treat type 1 diabetes.
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CHAPTER SEVEN
7

OVERALL CONCLUSIONS AND FUTURE DIRECTIONS

7.1 Overall conclusions
The objective of this project is to develop an effective strategy for the treatment of
type 1 diabetes using β-cell based replacement therapy. One novel approach to improve
the viability of transplanted β-cells is to transplant an optimal size range of β-cell
spheroids rather than a cell suspension. Uniform sized multicellular spheroids can be
coated with a thin layer of non-degradable hydrogel for immunoisolation. In addition, the
survival of spheroids of optimized size can be further improved with a novel coating of
multiple layers of human mesenchymal stem cells (hMSCs), a cell type that has profound
immunoregulatory effects, to prevent graft rejection. To prevent MSC migration away
from spheroids, another layer of non-degradable hydrogel can be added. To further
improve the viability and suppress the immune rejection, spheroids will be encapsulated
with nanoparticles loaded with angiogenic and immune regulatory molecules. By this
means the spheroid will passively evade the complications of stressors in addition to
actively modulating the immune microenvironment for regulatory tolerance and longterm engraftment.
In Chapter 2, we have attempted to provide a detailed overview of bioengineering
approaches for the treatment of type 1 diabetes, including insulin controlled release
systems, immunoisolation of transplanted islets, and cell-based therapies, such as β-cells
and stem cells.

In Chapter 3, we have created specific niche for β-cells in vitro. We have
optimized our hydrogel systems for MIN6 cells 3D culture. We have found that the
optimal condition for the cells to form artificial islets in vitro is the concentration of PEG
at 5% and the ratios of 4-arm thiolated PEG to PEGTA at 1:2 (or 1:3). Conjugation with
different peptides, especially, RGD at 0.2 mM, can significantly promote the insulin
secretion, similar to the 2D control group.
In Chapter 4, we have fabricated different sizes of uniform β-cell spheroids
through high-throughput automatic spheroids maker. Beta-cell spheroids with a diameter
of 200 µm exhibited the largest insulin secretion based on glucose stimulus when
compared to others with sizes of 100, 300, 400 and 500 µm. The novel core-shell
structured spheroids-hMSCs complex was achieved through coating methylcelluloe
hydrogel as physical barrier on the surface of β-cell spheroids to inhibit invasion of
hMSCs. Furthermore, hMSCs prevented apoptosis of β-cell spheroids and benefited
insulin secretion when exposed to pro-inflammatory cytokines.
In Chapter 5, LIF, IL-10 and VEGF loaded PLGA nanoparticles were
successfully fabricated through solvent extraction/evaporation technique. These growth
factors can be controlled to release over about 6 weeks. The bioactivity of released VEGF
has been confirmed by the in vitro HAEC proliferation assay. But the LIF and IL-10 did
not preserve glucose stimulated insulin secretion of β-cells in vitro when exposure to the
pro-inflammatory cytokines.
In Chapter 6, β-cell spheroids were transplanted under the kidney capsule to treat
diabetic mice. Beta-cell spheroids kept the glucose level of diabetic mice constant. Co-
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transplanted hMSCs suppressed the host inflammation response, activated the regulatory
T cells and also promoted angiogenesis at the transplantation site. The β-cell
spheroids/hMSCs/hydrogel complex initiated a mild inflammatory response. The LIF, IL10, and VEGF loaded complex further inhibited this response and promoted blood vessel
network formation at the transplantation site. Our approach holds a great potential to treat
type 1 diabetes.

7.2 Future directions
7.2.1

Hydrogels conjugated with functional peptides

7.2.1.1 Peptides with capacities of anti-immune response
In Chapter 5, we have constructed a hydrogel coated β-cell spheroids/hMSCs
complex. The outer layer of hydrogel is supposed to accommodate nutrients, oxygen, and
wastes diffusion out of the hydrogel. At the same time, the hydrogel will also permit proinflammatory cytokines and other effector molecules of low molecular weight, such as
IL-1β (17.5 KD) and TNF-α (51 KD), to enter the capsules. Besides the benefits of
hMSCs and LIF and IL-10 loaded nanoparticles to prevent the toxic effects of theseinflammatory cytokines, we want to conjugate cytokine-inhibitory peptides on the
hydrogel to further exert a protective effect on cells from damage induced by proinflammatory cytokines that were able to permeate the capsules.
A peptide inhibitor for cell surface IL-1 receptor (IL-1R) can block the interaction
between encapsulated cells and cytokines diffusing into the hydrogel. The IL-1R
inhibitory peptide sequence, FEWTPGWYQPY, has been reported [1] to conjugate to our
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hydrogels. This sequence can be designed as CCRRFEWTPGWYQPYWLC and be
synthesized by solid phase method.

7.2.1.2 Peptides with capacities of vascularization
A synthetic 15 amino acid peptide, KLTWQELYQLKYKGI, based on a region of
the vascular endothelial growth factor (VEGF) binding interface, has been shown to
possess similar biological activity to that of the VEGF protein [2]. Except VEGF loaded
nanoparticles, this sequence can be designed as CCRRKLTWQELYQLKYKGIWLC, be
synthesized by solid phase method, and can be conjugated to our hydrogels.

7.2.2

Adjusting the structure of β-cells spheroids-hMSCs complex

7.2.2.1 Optimizing the size of spheroids and the thickness of shell of hMSCs
Cells in aggregates or groups can form a community to provide paracrine
signaling or trophic support for neighboring transplanted cells to be able to survive in a
community manner. One important parameter in the spheroid structure is the size or
diameter. If the spheroid size is too big, the nutrient and oxygen support for the cells in
the core of the spheroid will be limited or insufficient. If the spheroid size is too small,
the beneficial impact of the multicellular community may be limited. Although we have
demonstrated high viability of spheroids of different sizes in vitro, there is an optimal
range of the spheroid size to get the highest survival rate for the transplanted β-cells in
vivo. In Chapter 6, it will be our further work to inspect the effects of the size of β-cells
on survival of transplanted cells. Moreover, the thickness of hMSCs will also affect the
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survival of β-cells in the core of spheroids. The optimal thickness of the shell of hMSCs
needs to be investigated further. Moreover, the fate of hMSCs after transplantation into
the tissue is a big issue we need to address.

7.2.2.2 Optimizing the hydrogel shell on the outlayer
In Chapter 5, we have selected agarose and PEG hydrogels to coat on the surface
of the β-cell spheroids/hMSCs complex. The functions of this hydrogel out layer lie in:
(1) to keep the complex intact during the transplantation process; (2) to prevent hMSCs
from migrating away from the spheroids, especially at the acute and sub-acute phase (1-3
weeks) because of the capacities of anti-inflammation and immunomodulation of hMSCs.
However, this layer of hydrogel definitely affects the transportion of oxygen and
nutrients to encapsulated cells in complex. Even PEG hydrogel is degradable through
hydrolysis in vivo, the optimal thickness of this out layer of hydrogel is something we
need to inspect.

7.2.3

Clinical use of our approaches

7.2.3.1 Cell source
Induced pluripotent stem cells (iPSCs) have been extensively studied in recent
years as they offer the potential to generate patient-specific cells for autologous use,
presumably avoiding the need for immunosuppression. The patient’s own fibroblasts can
be harvested and used to generate iPSCs. Induced pluripotent stem cells, as a source of βcells, have years of research ahead before clinical translations. It will be our future work
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to use iPSC-derived β-cells to fabricate spheroids and spheroids-MSCs complexs for
clinical use [3].
The hydrogel coated on the surface of the complex can prevent transplanted βcells from host immune response. Our selected hydrogel, methyl cellulose, is biodurable.
The resorption of cellulose in human tissues does not occur, since cells are not able to
synthesize cellulases [4]. The methyl cellulose is sufficiently nondegradable to enable use
of xenogeneic cells.

7.2.3.2 Our approaches for clinical use
As for clinical use, the spheroids will be fabricated from our robot spheroid maker
and can be cultured long-term in a floating flask on a shaker. The complex of spheroidshMSCs will be fabricated 3 days before transplantation. Sterilized hydrogel precursor
solutions through 0.22 µm filters and the complex can be transplanted into patients
through syringes.
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